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ABSTRACT 
Systemic sclerosis (SSc) is a rare connective tissue disease affecting skin 
and internal organs. The pathogenesis of SSc is multifactorial and includes 
autoimmunity, inflammation and vasculopathy. Pulmonary arterial hypertension 
(PAH) is among the most serious of SSc complications and is characterized by 
augmented vasoconstriction, neointimal remodeling and occlusion of small 
arteries in lung. Elevated pulmonary arterial blood pressure and volume overload 
in the right heart eventually lead to death from heart failure. Pre-existing elevated 
pro-fibrotic signaling, systemic vasculopathy and chronic inflammation are 
additional factors that likely contribute to the more severe PAH manifestation in 
SSc patients, whose response to existing therapies is suboptimal.  
The aim of my thesis research was to investigate the pathological role of 
altered transcriptional regulation of endothelium in pulmonary vasculature, as 
well as testing potential novel therapies for SSc-PAH in vivo. I found that 
  vii 
endothelial downregulation of GATA6 promotes increased production of reactive 
oxygen species (ROS) by suppressing enzymatic machinery responsible for ROS 
clearance. Increased ROS production triggered ER stress and inflammation, 
exacerbating endothelial dysfunction and vascular injury both in vitro and in vivo. 
Another discovery is that simultaneous depletion of two ETS-family factors, ERG 
and FLI1 synergistically activates interferon signaling in pulmonary endothelial 
cells and promotes inflammation in lung in vivo. Based on observed pathological 
contribution of oxidative stress and inflammation to vasculopathy and fibrosis I 
tested an anti-oxidative and anti-inflammatory agent- dimethyl fumarate (DMF) in 
mouse models of PAH, as well as lung and skin fibrosis. DMF efficiently 
ameliorated increased pulmonary artery pressure and vascular remodeling, as 
well as fibrotic changes in lung and skin. Mechanistically, I found that DMF 
promotes a proteasomal, βTRCP-dependent degradation of pro-fibrotic 
mediators TAZ/YAP, β-catenin and Sp1. 
In conclusion, I characterized new elements of pathological mechanism 
that promote vasculopathy and fibrosis, as well as provided an insight into anti-
inflammatory and anti-fibrotic DMF therapy. Importantly, elucidating the novel 
mechanism of DMF action and recognizing the pathological role of Hippo and 
Wnt signaling in fibrosis might help to design more specific and effective 
pharmacological intervention in SSc-PAH patients. 
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CHAPTER 1- INTRODUCTION 
Systemic Sclerosis (Scleroderma) 
Systemic sclerosis (SSc), also called Scleroderma, is a rare, multi-organ 
chronic connective tissue disease. The etiology of the disease is unclear, 
however some genetic and environmental factors, including pathogen infections, 
are thought to increase susceptibility for this disease. Pathogenesis of SSc is 
multi-factorial and involves autoimmunity, inflammation, vascular damage and 
fibrosis. The interplay between these processes leads to progressive endothelial 
dysfunction, degeneration of microvasculature causing severe tissue damage, 
and in extreme cases, tissue necrosis and gangrene. Cutaneous manifestation of 
this disease is often quite severe and debilitating, however the most lethal 
complications of SSc are pulmonary and cardiac involvements. There is no cure 
for SSc, and available therapies including anti-inflammatory, anti-fibrotic and anti-
proliferative drugs have proven to be effective to some degree in ameliorating the 
symptoms 1,2. 
Epidemiology and clinical manifestations of SSc 
Scleroderma is a rare disorder with the estimated incidence in the United 
States of 20 cases per-million population, and prevalence of 276 cases per-
million population. The peak onset occurs in individuals aged 30-50 years, with 
the female/male sex ratio between 6-9 3. Recent studies also revealed a higher 
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incidence rate in blacks than in whites, who in addition develop more severe 
disease and have worse outcomes when compared with other ethnic groups 4.  
There is no strong genetic link to SSc, however in US cohorts, it was 
found that first degree relatives have increased susceptibility to develop SSc with 
a relative risk of- 10 to 16. Genome-wide association studies (GWAS) suggested 
involvement of several genes implicated in immune system function. SSc 
patients had increased frequency of polymorphisms in the interferon-regulatory 
factor 5 (IRF5), involved in activation of interferon targets, and the ligand of 
CD134 (OX40L), involved in antigen presentation and T- and B- cell activation. 
Importantly, variants in IRF5 and signal transducer and activator of transcription 
4 (STAT4) were associated with susceptibility to pulmonary fibrosis 5. To date, 
several GWAS studies in SSc have revealed the major histocompatibility 
complex (MHC), particularly the HLA-DQB1 gene region to be the strongest 
susceptibility locus for SSc 5. A majority of these genetic variants are functionally 
linked to the immune system, therefore implicating the important role of immunity 
in pathogenesis of SSc. 
SSc encompasses a heterogeneous spectrum of disease ranging from 
skin thickening and fibrosis, digital ulcers and telangiectasia, to internal organ 
involvement, commonly accompanied by gastrointestinal problems and serious, 
often deadly pulmonary and cardiac complications. 
Based on the area of skin involvement, SSc patients are classified into limited 
and diffuse groups. The extension and degree of cutaneous change is quantified 
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by the modified Rodnan score, which is a subjective physical examination of skin 
thickness 6. Diffuse manifestation in the past was associated with increased risk 
of internal organ involvement, however recent studies demonstrate that both 
groups have similar predispositions to those complications (Table 1) 7.  
 
 
Table 1 Clinical features of SSc according to classification group. Table from 8 
 
The most common skin manifestation, affecting almost 95% of patients, is 
Raynaud’s phenomenon, a vasospasm in the fingers and toes in response to 
cold temperature. This usually precedes the diagnosis of SSc, however alone is 
not diagnostic of SSc, since Raynaud’s phenomenon also commonly occurs in 
other diseases 9. 
Skin fibrosis and thickening normally begins on the fingers as the disease 
progresses, extends proximally to the limbs, back and face 1. Figure 1 shows a 
stained section of SSc skin with characteristic immune cell infiltration (A,B), 
deposition of extracellular matrix (ECM), comprised mostly of collagen (C), as 
well as thickening of the dermis and reduction of fat in the hypodermis 1. 
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Figure 1 H&E staining of skin sections from SSc patients. (A) early diffuse 
cutaneous SSc (B) inflammation in early diffuse cutaneous SSc (C) established 
fibrosis. Figure from 1. 
 
Other skin complications include digital ulcers and fingertip pitting scars, 
which are present in 42% of diffuse and 33% of limited forms. They can lead to 
pain, infection, functional impairment, gangrene and eventually amputation. 
Other forms of skin disease include limbs ulcerations (40%), telangiectasia 
(75%), hyperpigmentation of thickened skin (30%), and cutaneous calcifications 
affecting soft tissues, fingers, forearms, elbows and knees (25%) (Table 1).  
Pulmonary involvement is the most common cause of death in SSc 
patients and includes interstitial lung disease (pulmonary fibrosis) and pulmonary 
arterial hypertension (PAH), as well as a mixture of those two. Prevalence of 
pulmonary complications in different groups of SSc is presented in Table 1.  
Pulmonary fibrosis (lung section shown in Figure 2), like skin fibrosis, is 
characterized by increased immune cell infiltration and deposition of ECM, which 
leads to a decrease in alveolar spaces and eventually a significant deterioration 
of lung function 10. Patients with SSc-associated lung fibrosis are predominantly 
women between the ages of 30 and 55 years, however it is estimated that up to 
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90% of SSc patients will develop some degree of lung fibrosis during the 
progression of their disease. 
 
 
Figure 2 H&E staining of lung section of SSc patient with interstitial pneumonia 
showing patchy interstitial fibrosis next to unaffected lung tissue. Figure from 10. 
 
Cardiac complications in SSc are relatively rare, but are very serious, and 
manifest as pericarditis and myocardial fibrosis. In addition to the left ventricular 
problems, SSc patients with PAH experience right ventricular hypertrophy and 
right heart failure 7. 
Though relatively uncommon, kidney involvement leads to renal failure, 
affecting 4%-6% patients (Table 1). However, when impaired kidney function is 
diagnosed early, renal failure can be efficiently prevented with the use of 
angiotensin-converting enzyme (ACE) inhibitors 11.  
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Pathogenesis of SSc 
The interplay of autoimmunity, vasculopathy and fibrosis orchestrate the 
disease onset and progression. Here I discuss the contribution of each 
component, as well as their interactions in the pathogenesis of SSc. 
Vasculopathy and endothelial dysfunction 
Vascular injury and endothelial cell activation are possibly the earliest 
events in disease pathogenesis. The initial trigger in vascular injury is thought to 
be endothelial damage and activation. The injury might be initiated by the 
presence of circulating autoantibodies, pathogens, cytokines, and reactive 
oxygen species (ROS). As observed in SSc patients-derived endothelial cells, 
activated endothelium overexpress adhesion molecules (ICAM-1, GlyCAM-1) 
and pro-inflammatory cytokines (IL-6, TNFα) 12,13. Subsequently, circulating 
immune cells become activated and infiltrate the tissue, where they promote 
fibrotic process through interaction with fibroblasts. Activated endothelial cells 
also produce and secrete growth factors, including TGFβ and PDGF, that 
promote proliferation of vascular smooth muscle cells (SMCs), pericytes and 
adventitial fibroblasts, leading to vascular remodeling and obliterative fibrosis 14.  
The response of endothelium to external injury signals as well as 
maintaining an inactive or quiescent state in the absence of such signals is 
regulated largely on the transcriptional level. The transcriptional machinery 
integrates these extracellular signals, resulting in a gene expression response 
that is appropriate for physiologic or pathologic conditions. 
  
7 
Gene expression in adult ECs is mediated by combinatorial interactions 
between non-endothelium-specific transcription factors, including Sp1, GATA 
proteins (GATA2, GATA3, and GATA6), as well as endothelial specific ETS 
family of transcription factors (ETS1, ETS2, ELF1, NERF2, FLI1 and ERG) 15. 
ETS factors are central to the transcriptional systems controlling ECs gene 
expression, as the majority of characterized endothelial specific genes promoters 
and enhancers contain ETS binding motifs. ETS transcription factors are known 
to promote expression of genes involved in maintaining endothelial barrier 
integrity and simultaneously repress the expression of pro-inflammatory genes, 
therefore ensuring quiescent non-activated state of the endothelium 16. 
In addition treatments of ECs with stress-inducing factors such as hypoxia, 
chemokines, cytokines, growth factors and vasoconstrictors revealed that 
responses to stress include combinatorial action of transcriptional regulation via 
NFkB, AP-1, STAT3, HIF1 and NRF2 15,17-19.  
Prolonged endothelial cell activation eventually progresses to endothelial 
dysfunction, characterized by imbalance in vascular tone and increased vascular 
permeability. Decreased production and bioavailability of the vasodilator nitric 
oxide (NO), together with the increased expression of vasoconstrictor endothelin 
1 (ET-1) results in enhanced vasoconstriction. NO signaling is also suppressed 
by diminished response of the vessel to sheer stress, caused by an increase of 
vascular stiffness during vascular remodeling. The balance of molecules 
promoting vasodilatation to vasoconstriction not only coordinates vascular tone, 
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but also serves to inhibit ECM deposition and prevent SMCs proliferation 20-22. 
Many pathophysiological responses in the vessel wall are caused by the 
overabundant reactive oxygen species (ROS). Changes include altered balance 
between EC proliferation and apoptosis, which can lead to excessive 
angiogenesis or loss of endothelial cells as well as inactivation of NO 20. 
Altered vascular function is only one of the characteristics of vasculopathy 
in SSc. Equally important are the structural changes of the blood vessels and the 
microvascular system as a whole. Progressive loss of peripheral microvessels, 
seen in SSc, may result in tissue damage and ischemia. Loss of 
microvasculature in SSc-PAH is caused by occlusion of the blood vessels by 
hyperproliferative cellular components and simultaneous lack of compensatory 
vasculogenic and angiogenic signaling 23-25.  
Vasculogenesis is a process of vascular remodeling by bone marrow-
derived endothelial progenitor cells (EPCs) that are recruited to the place of 
vascular injury. In SSc, altered vasculogenesis is due to a decrease number of 
EPCs coupled with dysfunction and impaired recruitment of EPCs 26-29. 
The process of new vessel sprouting from the existing vessel with the 
simultaneous proliferation and migration of mature endothelial cells is called 
angiogenesis and is disregulated in SSc 30,31. 
Autoimmunity and inflammation 
The immune system plays a pivotal role in triggering and advancing 
vasculopathy and fibrosis in SSc. Immune infiltrates, predominantly perivascular, 
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have been shown in the skin early in the disease progression of SSc, and consist 
of T cells, monocytes/macrophages and dendritic cells.  
T cells present in the immune infiltrates are biased toward Th2, which are 
characterized by secretion of IL-4 and IL-13 and stimulation of B cells 32,33. IL-
4/IL-13, elevated in serum and bronchioalveaolar fluid from SSc patients, drive 
M2 differentiation of macrophages, which secrete large amount of TGFβ 34. In 
vitro, stimulation of fibroblasts with IL-4/IL-13 induces TGFβ-independent 
induction of collagen synthesis. 
Another component of immune infiltrate are dendritic cells, the main 
producer of CXCL4. CXCL4 is elevated in the plasma and the skin of patients 
with SSc, especially in early disease, and the levels are correlated with disease 
progression. In vitro, CXCL4 induces endothelin-1 (ET-1) and activates Toll-like 
receptors (TLRs). In an animal model, CXCL4 induces tissue infiltration by 
inflammatory cells and skin thickening. In addition, upregulation of CXCL4 is 
associated with lung fibrosis and PAH 35. 
Involvement of B cells in SSc pathogenesis is strongly suggested by the 
presence of several autoantibodies. The most frequently found autoantibodies 
are anti-centromere (ACA) in 15%–43% of patients, anti-topoisomerase I (anti-
Scl70) in 21%–34%, anti-RNA polymerase III in 5% and anti-RNP in 5%. They 
are associated with distinct disease subtypes and with differences in disease 
severity, including extent of skin involvement, internal organ manifestations and 
prognosis, and are useful in establishing therapeutic strategies.  Other 
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autoantibodies found in SSc include anti-endothelial cell antibodies, anti-fibrillin-1 
antibodies, anti-matrix metalloproteinases and anti-platelet-derived growth factor 
receptor. There is growing evidence that these antibodies might directly trigger 
vascular injury 36.  
A contribution of innate immune system to the pathogenesis of SSc has 
been suggested by recent observations of an interferon ‘signature’ expression 
profile in SSc PBMCs and elevated cytokines in serum. Increased activity of Toll 
like receptors (TLRs) has been correlated with SSc and might lead to activation 
of pro-fibrotic pathways like TGFβ 37. In addition, activated TLRs stimulate 
secretion of pro-fibrotic cytokines. Serum levels of IL-6 and IL-1β, known 
stimulators of collagen secretion by fibroblasts, along with TNFα and IL-10, were 
found to be increased in SSc patients 38,39.  
IL-6 is a cytokine of special interest in SSc. Produced by immune cells as 
well as fibroblasts and endothelial cells, IL-6 directs toward Th2-skewed 
immunity, inflammation and fibrotic responses. In experimental models, IL-6 in 
vitro induces collagen expression and in vivo depletion of IL-6 protects mice from 
fibrosis. High levels of IL-6 have been reported in SSc plasma and they correlate 
well with the disease severity and progression 39,40. 
Fibrosis in SSc 
The mechanistic basis of fibrosis in SSc is only partially understood 
despite considerable advancements made in the last two decades. As shown in 
Figure 3, the process of fibrosis in SSc starts with an initial injury that then 
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initiates a chain reaction of pathological events. Initiation, susceptibility, 
vasculopathy, contribution of inflammation and autoimmunity were already 
discussed in previous sections. Here I will describe the known mechanisms of 
fibroblasts activation in SSc, which leads to ECM deposition (‘tissue remodeling’ 
and ‘excessive scarring and fibrosis’ in Figure 3). 
 
Figure 3 Schematic illustrating contribution of different mechanisms to fibrosis. 
Figure from 14. 
 
 
 
ECM consists of a cellular compartment (resident and infiltrating cells) and 
a connective tissue compartment (collagens, proteoglycans, fibrillins, lamin, 
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fibronectin). Also present in ECM are TGFβ and CTGF, soluble factors, which 
control mesenchymal cell proliferation, differentiation, function, and survival. 
Mesenchymal cells consist largely of ECM-secreting fibroblasts that have been 
activated either by soluble factors in an autocrine and/or paracrine manner, or by 
cell-cell or cell-ECM interactions (Figure 3, boxes 4 and 5). Impaired ECM 
degradation and remodeling by matricellular proteins further contributes to ECM 
accumulation 41.  
Collagens, the most abundant ECM component, belong to a large family 
of proteins that in normal physiological conditions play essential role in organ 
development, growth and differentiation, as well as tissue regeneration after 
injury. Almost all collagen genes contain conserved transcription factor binding 
motifs in their promoters. Combinatorial binding of ubiquitous and tissue specific 
transcription factors (TF)s such as SP1, SMAD3, ETS1, early growth response 1 
(EGR-1), and CCAAT-binding factor activate collagen gene transcription while 
SP3, CCAAT/enhancer binding protein, Y box-binding protein 1, c-KROX, and 
FLI-1 suppress it. The function of these TFs is further regulated by interaction 
with transcriptional co-factors (p300/ CREB-binding protein, p300/CBP–
associated factor), chromatin modifying enzymes (histone deacetylases) and 
post-translational modifications. Alterations in the protein levels, their activities 
and binding partners contribute to persistent ECM production and fibrosis 1. 
The main source of excessive ECM in SSc are activated fibroblasts 
(myofibroblasts), which in normal physiological conditions are essential for 
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wound healing. Upon injury, myofibroblasts produce ECM to build support for 
cells mediating healing and contraction of the wound.  When wound closure is 
complete, myofibroblasts deprived of stimuli such as pro-inflammatory cytokines 
or growth factors generated in the local cellular microenvironment by platelets, 
endothelial cells, epithelial cells and inflammatory cells, undergo apoptosis. In 
SSc, chronic inflammation and deregulation of pro-fibrotic signaling sustains 
myofibroblast activation (Figure 3, box 4) 42. Possible sources of myofibroblasts 
in the tissue include postembryonic fibroblasts, bone marrow–derived fibrocytes, 
pericytes, adipocyte progenitors, as well as epithelial and endothelial cells 
through the process of epithelial- and endothelial- to mesenchymal transition 43. 
Endothelial to mesenchymal transition (EndoMT) might be activated 
during vascular injury and is thought to provide excess mesenchymal cells- 
fibroblasts to drive fibrotic processes in SSc. The evidence of EndoMT in fibrosis 
comes from animal studies, where bleomycin-induced fibrosis was blocked by 
inhibition of c-Abl and PKC-∂, key molecular players in the EndoMT process 44,45. 
Importantly, similar inhibition improved outcomes in SSc patients with PAH 46. 
Misregulation of several different signaling pathways can lead to fibroblast 
activation. The well studied pro-fibrotic mediators - transforming growth factor 
(TGFβ) and TGFβ receptors are upregulated in SSc patients 47,48. TGFβ is 
secreted during injury by macrophages, dendritic cells, activated endothelial cells 
and by activated fibroblasts themselves. During the healing process, secreted 
TGFβ attracts inflammatory cells and fibroblasts, and promotes cell proliferation, 
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differentiation and survival 49. In pathophysiological conditions such as SSc, 
excessive TGFβ signaling leads to constitutive activation of the SMAD dependent 
and SMAD independent pro-fibrotic pathways. SMAD dependent pathways are 
mediated through type I (ALK1 and ALK5) and type II TGFβ receptors whose 
tetramerization and autophosphorylation upon ligand binding leads to a signaling 
cascade through SMAD2/3 or SMAD1/5/8, which act together with other 
transcription factors and co-activators to regulate gene expression 50. Signaling 
through type I and type II receptors can lead to pro- and anti-fibrotic effects in 
various cell types under physiological conditions, although in SSc fibroblasts both 
ALK1 and ALK5 receptors activate pro-fibrotic signaling 51,52. The main target 
genes of SMADs are: connective tissue growth factor (CTGF), ET-1, tissue 
inhibitors of metalloproteinases (TIMPs), plasminogen activator inhibitor-1 (PAI-
1) and ECM proteins including several isoforms of collagen and fibronectin 53. 
TGFβ signaling is also interconnected with several other cellular signaling 
pathways that are required for transcriptional activation of key TGFβ target 
genes, including the p38 MAP kinase cascade, the JNK /c-jun pathway and the 
ras/MEK/ERK MAP kinase cascade 54,55.  
Sustained TGFβ signaling can result in induction of oxidative stress.  It 
has been demonstrated that TGFβ positively regulates expression of NOX4 
enzyme in fibroblasts 56. SSc fibroblasts have been shown to constitutively 
produce excessive amounts of ROS via NOX enzymes, which was sufficient for 
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the induction of collagen production and cell proliferation 57. Free radicals may 
also contribute to the development of fibrosis by promoting inflammation. 
CTGF is a soluble protein that controls cell attachment and migration, 
modulates the activity of TGFβ and regulates cell differentiation, proliferation, 
apoptosis, and ECM synthesis. Although expressed at very low levels in normal 
tissues, CTGF expression is induced by TGFβ as well as ET-1 and hypoxia. The 
levels of CTGF are elevated in fibrotic tissues in SSc and in mouse models of 
fibrosis. Additionally, CTGF levels are increased in dermal blister fluid and in 
blood from patients in a manner that correlates with disease activity 58. CTGF is a 
necessary co-factor for TGFβ to activate and sustain ECM production in the 
context of disease 59.  
Previously mentioned endothelin-1 (ET-1), apart from being a strong 
vasoconstrictor, is also an important pro-fibrotic mediator. ET-1 can stimulate 
fibroblast collagen production, the down-regulation of MMP-1, an important 
matrix remodeling protein, and the contraction of fibroblast-populated collagen 
lattices. Circulating levels of ET-1 are elevated in SSc patients and correlate with 
skin fibrosis and disease. Overabundance of ET-1 protein has been 
demonstrated in blood vessels, lungs, kidneys and skin of SSc patients. ET-1 
can also augment pro-inflammatory signaling and promote smooth muscle cell 
proliferation, contributing to the pathogenesis of PAH 14,60,61.  
Wnt pathway is essential both for development and maintenance of tissue 
homeostasis and there has been substantial evidence suggesting it might be one 
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of the major mediators of fibrosis in SSc 62,63. Constitutive activation of Wnt 
effector β-catenin has been observed in skin and lung of SSc patients and in 
animal models of fibrosis 64-66. Importantly, inhibition of Wnt/β-catenin prevents 
fibrosis and pulmonary hypertension in experimental models 67-69. It is not yet 
known whether Wnt/β-catenin is an independent pro-fibrogenic factor, since β-
catenin does not directly regulate expression of ECM genes. It is known, 
however, that Wnt signaling promotes pro-fibrotic response through interaction 
with TGFβ and Hippo pathways 70.  
In addition to responding to soluble factors in autocrine/paracrine fashion, 
fibroblasts can also be activated through mechanosensing. Fibrotic tissue, 
characterized by increased stiffness, is sensed by fibroblasts through cell surface 
integrins, and then the signal is transduced via focal adhesion kinase and RHO-
associated kinase. Downstream from this signaling cascade the ultimate 
effectors are the Hippo pathway proteins: Yes-associated protein (YAP) and WW 
Domain-containing Transcription Regulator Protein 1 (TAZ). These two proteins 
are transcriptional co-activators of an array of pro-proliferative and pro-fibrotic 
genes including CTGF and ET-1. Therefore, mechanosensing via the Hippo 
pathway might be an important contributor to perpetuating fibroblast activation 
and exacerbating fibrosis 70,71. The role of TAZ/YAP in fibrosis has been 
demonstrated in animal models as well as TAZ/YAP hyper-activation was 
detected in patients with lung fibrosis 72,73. 
Important mechanisms regulating fibroblasts activity are transcription 
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factors and epigenetic modifications 74. Transcription factor Friend leukemia 
integration factor-1 (FLI1) has been shown to play an important role both in 
fibrosis and vasculopathy in SSc and is expressed predominantly in endothelial 
and hematopoietic cells and to a lesser extent in fibroblasts 75.  Initial studies 
linked FLI1 to SSc pathology by showing decreased protein and transcript levels 
of FLI1 in SSc dermal fibroblasts. Importantly, FLI1 is an inhibitor of type I 
collagen gene transcription, which is the most abundant ECM protein in SSc 
fibrotic lesions 76-78. FLI1 binds COL1A2 promoter together with Sp1 suppressing 
its transcription 79. FLI1 deficiency also leads to upregulation of the fibrogenic 
genes, including CTGF and αSMA 75,80. The interaction between FLI1 and TGFβ 
is bi-directional, where on the one hand FLI1 represses the TGFβ-induced pro-
fibrotic gene program, whereas TGFβ abrogates FLI1 function by targeting it for 
degradation.  This process involves protein kinase C (PKC) δ dependent 
phosphorylation and subsequent p300/CREB-binding protein-associated factor 
(PCAF)-dependent acetylation 81,82. Furthermore, pro-fibrotic events might 
include direct repressive modifications to the FLI1 promoter, including 
methylation and histone deacetylation. Consistent with in vitro experiments in 
cultured fibroblasts, experiments in mice show that expression of inactive Fli1 in 
mice promotes collagen type I expression, while Fli1 haploinsufficiency 
exacerbates dermal fibrosis in a bleomycin mouse model 83.  
Beside transcription factors, chromatin modifications play an important 
role in promoting fibrosis. Genome wide methylation studies show differential 
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patterns of CpG islands methylation as well as general increase in chromatin 
methylation in SSc fibroblasts 84. Among the genes involved in fibrotic process 
that had altered promoter methylation were FLI1, inhibitors of Wnt signaling 
DKK1, WIF1 and SFRP1, as well as genes controlling regulatory T – (Treg) cell 
function including FOXP3 85,86. Acetylation of DNA also plays a role in SSc and 
despite observed hypo- and hyper- acetylation, inhibition of HDAC results in 
suppression of fibrotic responses in fibroblasts 87.  
Control of transcription through microRNA has been recently implicated in 
pathogenesis of SSc with miR-21 and miR-29 being of particular interests 88. 
Elevated in SSc, miR-21 negatively regulates the inhibitor of pro-fibrotic signaling 
SMAD7, whereas when it is downregulated, such as in patient-derived 
fibroblasts, miR-29 has inhibitory effect on fibrogenic gene expression 89,90.  
Current therapies 
There is no cure for SSc, however several treatment regimens are able to 
sub-optimally ameliorate disease symptoms 8. Skin fibrosis can be partially 
reversed by the use of anti-autoimmune chemotherapeutics including 
cyclophosphamide, methotrexanate, intravenous immunoglobin infusion and 
monoclonal antibodies targeting B cells (Rituximab). Nonetheless, anti-fibrotic 
tyrosine kinase inhibitors and TGFβ inhibitors have been tested with mixed 
results and serious adverse effects in clinical trials. Lung fibrosis in SSc is 
primarily treated with cyclophosphamide. The treatment that can significantly 
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improve skin and lung fibrosis, but is related to a high risk of death, is a high-
dose immunosuppressive therapy followed by autologous hematopoietic stem 
cell transplant. 
For management of Raynaud’s phenomenon and digital ulcers the most 
commonly used drugs are vasodilators including calcium antagonists, 
angiotensin II- receptor antagonists, and ACE inhibitors. ACE inhibitors are also 
a very effective treatment for renal complications.  
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Pulmonary arterial hypertension (PAH) 
Classification of pulmonary hypertension 
Pulmonary hypertension (PH) is a spectrum of disease characterized by a 
mean pulmonary artery pressure (PAP) greater than 25 mm Hg at rest, as 
measured by direct catheterization. Pulmonary arterial hypertension (PAH) is a 
sub-group of PH with a specific etiology, where elevated PAP is due to extensive 
vascular remodeling of small pulmonary arteries. PAH is characterized by 
endothelial dysfunction, SMCs hyperproliferation, medial thickening and 
neointimal hyperplasia. Occlusion of the vascular lumen leads to increased PAP, 
increased load on the right heart, leading to its hypertrophy and eventually heart 
failure 91,92.  
PH is currently classified into five groups: pulmonary arterial hypertension 
(Group 1); pulmonary hypertension due to left heart disease (Group 2); 
pulmonary hypertension due to chronic lung disease and/or hypoxia (Group 3); 
chronic thromboembolic pulmonary hypertension (Group 4); and pulmonary 
hypertension due to unclear multifactorial mechanisms (Group 5) 93.  
Group 1 of PH can be further categorized as idiopathic PAH, heritable 
PAH, drug- and toxin- induced PAH, or disease associated with PAH, resulting 
from HIV infection, congenital heart disease or connective tissue disease like 
SSc. Some SSc patients also fall into group 3, where PH is primarily caused by 
pre-existing interstitial lung fibrosis and is not initiated by vascular changes 93. 
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 Vascular remodeling in center of PAH pathogenesis  
The key feature of PAH is an injury and dysfunction of endothelium 94. The 
etiology of endothelial cell injury and activation in SSc was explained in detail in 
previous sections. Activated endothelial cells produce and secrete pro-fibrotic 
(CTGF, PDGF, TGFβ, ET-1) and pro-inflammatory (TNFα, IL-6, IL-8, CCL2, 
OSM, ICAM) factors which further attract immune cells that penetrate the tissue 
and send proliferative and activating signals to surrounding smooth muscle cells 
(SMCs) and fibroblasts as shown in Figure 4 95. 
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Figure 4 Schematic illustrating vascular changes in PAH. Figure from 95.  
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An impaired endothelial barrier also promotes thrombosis, which 
increases the risk of developing clots that block blood flow and leads to tissue 
hypoxia, one of the pathological drivers of vascular remodeling 96. Chronic 
endothelial activation leads to endothelial dysfunction, characterized by 
decreased NO bioavailability, increase in vasoconstrictors (ET-1) and ROS 
production. Accordingly, patients with SSc-PAH have lower levels of exhaled NO, 
excessive expression of ET-1 and elevated levels of reactive oxygen species 
(ROS) 97. 
Oxidative stress can directly influence proliferation and other functions of 
pulmonary smooth muscle cells In SMCs, oxidative stress induces a switch to a 
proliferative phenotype by increasing intracellular calcium and decreasing 
expression of contractile phenotypic markers, while simultaneously enhancing 
the expression of proliferative phenotypic markers and growth factors (TGFβ, 
PDGF, VEGF). ROS overabundance can also promote proliferation and 
activation of adventitial fibroblasts 98. 
SMC proliferation and fibroblast activation are initial steps in the 
development of hypertension resulting in vascular occlusion and diminished 
vascular capacity. Interestingly, activated endothelium may release factors that 
either stimulate SMC proliferation, such as FGF-2 or PDGF, or fail to produce 
agents that inhibit proliferation of SMCs in response to growth factors, such as 
apelin 95. The mechanism of hyperproliferation of SMCs in PAH is not fully 
understood, although several factors are known to initiate this process including 
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ET-1, NO, ROS. ET-1 in SMC signals through ETA receptor, which upon binding 
a ligand causes rapid increase in calcium levels and sustained PKC activation. 
ET-1 also activates MAPK signaling which together with activated PKC promotes 
cell growth, survival and proliferation 99,100. NO is another molecule of interest, as 
in addition to being a potent vasodilator, is also an inhibitor of SMC proliferation. 
As mentioned before, the bioavailability of NO in pulmonary vasculature in PAH 
patients is severely depleted. 101. Vasoconstriction and SMC proliferation can be 
additionally promoted via signaling through the calcium and potassium channels 
102-104. In hypoxic conditions mitochondria of SMC are damaged by altered 
potassium channel function, leading to excess production of ROS that triggers 
proliferative cell phenotype 105.  
Regulated mostly by mitochondria, metabolic changes in SMC, as well as 
ECs and fibroblasts, are one of the central players in vascular remodeling. 
Primarily associated with cancer cells, metabolic switch from oxidative 
phosphorylation to aerobic glycolysis (Warburg effect), has also been implicated 
in PAH pathogenesis 106. Those metabolic changes promote inflammation, 
excessive proliferation and resistance to apoptosis 107.  
Bone morphogenetic protein (BMP) receptor type 2 (BMPR2) is a receptor 
mutated in approximately 70% cases of familial PAH and 30% of idiopathic PAH, 
but there is also evidence that its function might be inhibited by hypoxia and 
other stress factors, and even patients with no evidence of mutation have 
lowered BMPR2 expression 108. Signaling through BMPR2 in physiological 
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conditions ensures normal cell growth, proliferation and apoptosis. In 
pathological conditions such as PAH ECs apoptosis and SMCs proliferation is 
being promoted, which has a profound effect on vascular remodeling. 
In recent years the role of perivascular stem-like cells called pericytes has 
been increasingly recognized for their role in maintaining vascular homeostasis 
and also taking part in vascular remodeling process. Pericytes are important 
regulators of vascular development, stabilization, maturation, remodeling and 
tone, but also modulate EC proliferation, SMC contraction and immunity. They 
reside in the interface between circulating blood and interstitial space at close 
proximity to ECs and SMCs 109. Pulmonary vascular remodeling is accompanied 
by an increase in pericyte density and coverage in distal pulmonary arteries. 
Proliferative and migratory endothelial-derived factors in PAH may promote 
vascular pericytic coverage. Pathogenic property of pericytes could include their 
stem-cell-like potential to trans-differentiate into vascular SMCs and fibroblasts. 
Consistent with this scenario, exogenous TGF-β and hypoxia promotes pericyte 
differentiation into contractile SM-like cells in culture and experimental animal 
models 110,111. 
Vascular changes in PAH are also promoted and exacerbated by 
activated adventitial fibroblasts. As mentioned before, activated fibroblasts are 
the main source of ECM, adding to vessel wall stiffness in a process that further 
increases PAP. In addition, activated fibroblasts have been shown to actively 
mediate inflammatory processes by producing IL-6, CCL2 and IL1b, which 
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recruit, retain, and activate naïve macrophages toward a pro-inflammatory/pro-
remodeling phenotype 112.   
Role of immune system in PAH pathogenesis 
Inflammation has been widely recognized as a major driving factor of 
vascular remodeling in PAH and there is a clear correlation between degree of 
perivascular inflammation, wall thickness and PAP 113. Elevated serum levels of 
several chemokines, cytokines and increased perivascular infiltration by B cells, 
cytotoxic T cells, macrophages and dendritic cells (as shown in Figure 5) has 
been observed in PAH patients 114,115.  
 
 
Figure 5 Schematic illustrating Impact of different dysregulated immunological 
pathways in promoting vascular remodeling in PAH. Figure from 115. 
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Found in perivascular immune infiltrate, T cells play multiple roles in 
development of PAH as shown in Figure 5. Major component of infiltrate consists 
of cytotoxic CD8+ T cells, that promote cytokine gene expression through, 
elevated in PAH, and NFAT (nuclear factor of activated T cells) 116. Another sub-
group of T cells- regulatory T cells (Tregs)- are believed to have a protective 
effect on endothelium and might prevent development of PAH through 
upregulation of BMPR2 in lung tissue 117. Tregs depletion can also trigger 
skewing toward TH1/ TH17 immunity, leading to activation of macrophages 118. 
Elevated levels of antinuclear antibodies are observed in PAH patients, 
which might imply involvement of B cells in the pathobiology of PAH 119. Indeed, 
immune infiltrate in vascular lesions is enriched in B cells. Interestingly, gene 
profiling of B cells derived from healthy controls and iPAH patients showed 
profound changes in gene expression between these two groups 120. 
The fibroproliferative lesions in PAH patients are enriched in macrophages 
and it has been observed that majority of them switch their phenotype to the 
more activated one (alternatively activated, M2 macrophages). The switch might 
be caused by the IL-6, which is one of the most abundant cytokines in PAH. 
118,121,122. Activated macrophages upregulate expression of genes involved in the 
inflammatory process (IL-1b, IL-6, TNFα, Il-13) therefore additionally amplify the 
innate immune response. Macrophages may also activate T cells and produce 
ET-1 123,124. 
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Cytokines serve as the signaling proteins in many of biological processes 
such as inflammation, immunity and hematopoiesis. Secreted by variety of 
immunological cells, cytokines can signal in autocrine, paracrine and endocrine 
fashion. Plasma of PAH patients often contains elevated levels of several 
cytokines (IL-1b, IL-18, IL-6, IL-8, IL-13 and TNFα) and studies in animals 
indicate the essential role of cytokines and cytokine producing cells in 
pathogenesis of PAH 114. Importantly, the levels of cytokines correlate more 
strongly with the patient’s outcome than traditional measurements such as 6 
minute walk test or hemodynamics, supporting the idea of cytokine levels as a 
good diagnostic biomarker 125. Mechanistically, cytokines can promote SMC 
proliferation (IL-18), migration (IL-18) and survival (TNFα) as well as promote 
vasoconstriction (IL-13, TNFα) and ECs proliferation (IL-8) 126-131. 
IL-6 is produced by macrophages and T cells, as well as non-immune 
cells including fibroblasts and ECs, and is the most important cytokine in PAH. In 
animal studies downregulation of IL-6 by anti-inflammatory drugs significantly 
reduced pulmonary vascular muscularization and right heart hypertrophy 132,133. 
Consistent with the role of IL-6 in promoting vascular remodeling, overexpression 
of IL-6 in mouse led to severe pulmonary hypertension closely resembling 
pathological features of human disease 134. Mechanistically, there are several 
proposed pathways through which IL-6 promotes PAH. Animal studies show IL-6-
mediated downregulation of BMPR2, upregulation of expression of MMP-9, 
VEGFR2 and VEGF 134,135.   
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The chemokines of particular interest in PAH, shown to be increased in 
patients’ plasma, include fractalkine (CX3CL1), CCL2 and CCL5 136. Those 
chemokines promote SMCs proliferation (fractalkine), monocyte migration 
(CCL2) and induction of ET-1 expression (CCL5) 137-139. 
 
SSc-associated PAH 
SSc-PAH shares many pathological aspects with iPAH, however pre-existing 
serious systemic disorder plays a role in worsening both prognosis and treatment 
outcomes 140.  
The key differences between idiopathic and SSc-associated PAH are 
autoimmunity and fibrosis. Levels of anti- ETA receptor and anti-angiotensin type 
1 receptor antibodies as well as anti-fibroblast IgG were significantly higher in 
patients with SSc-PAH compared to other forms of PAH 141.  
It has been well documented that the survival in SSc-PAH is significantly 
worse than in iPAH, despite less severe pulmonary hemodynamics. That could 
be partially explained by demographics of patients, where SSc-PAH patients are 
up to a decade older than iPAH patients at the time of diagnosis. SSc-PAH 
patients also demonstrate worse right ventricle contractility and poorer coupling 
of right ventricle contractility with afterload, even in the absence of pre-existing 
heart fibrosis 142. Interestingly, several groups have demonstrated that interstitial 
lung disease (ILD)- associated pulmonary hypertension in SSc (group 3 in PH 
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classification) is associated with a significantly poorer survival than SSc-PAH, 
despite similar pulmonary hemodynamics 143.  
 
Current therapies 
Current strategies for the treatment of PAH include targeting deficiencies 
in either NO signaling (PDE-type 5 inhibition), enhancing nucleotide signaling via 
cAMP PGI2 (prostacyclin analogs), or limiting excessive ET-1 effects (ET 
receptor blocker). To date, the most successful approach to enhancing NO–
cGMP signaling has been the use of PDE-5 inhibitors, such as sildenafil and 
tadalafil 144.  
Currently, the most effective treatment for SSc-PAH is ET receptor 
blocker. It is now recognized that fixed mechanical vascular obstruction with loss 
of cross-sectional area, rather than vasospasm, is the predominant cause of 
increased PAP in most SSc-PAH patients. Indeed, only 12.6 % of patients 
respond to potent vasodilators, such as inhaled NO 143.  
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CHAPTER 2- MATERIALS AND METHODS 
 
Mice 
Male C57BL/6 mice were purchased from The Charles River. All 
experiments were performed under the guidelines of the Boston University 
Institutional Animal Care and Use Committee (protocol AN-15037).  
Dimethyl fumarate (Sigma Aldrich) ip injections were performed daily with 
a dose of 90 mg/kg. DMF was dissolved in DMSO (30mg/ml) and mixed with pre-
warmed (37°C) vehicle (10% (2-Hydroxypropyl)-β-cyclodextrin (Sigma Aldrich) in 
PBS) immediately prior to injection. The volume of a single injection was 500 µl.  
For hypoxic conditions, 6-week old mice were placed in a hypoxic chamber (10% 
oxygen) (BioSpherix).  
Erg+/-Fli1+/- mice used for experiments were 6-8 weeks old, both male and 
female, on a C57BL/6 genetic background. The derivation of Erg+/- and Fli1+/− 
mice has been described previously 145-147.  
Bleomycin (Hospira) or PBS was delivered in Alzet osmotic miniature 
pumps (model 1007D) at a dose of 1.8 unit/mouse and mice were sacrificed after 
4 weeks. Mice with bleomycin pumps were injected with DMF daily for the 
duration of the entire experiment starting the day after surgical installation of 
pumps. 
Pulmonary endothelial cells were isolated using AutoMACS (Miltenyi 
Biotec) technology according to the manufacturer instructions using double 
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selection with CD45 and CD31 antibodies. Cells were grown on slides coated 
with Collagen I. 
 
Hemodynamic measurements 
Transthoracic echocardiography was performed using a Vevo 770 High-
Resolution Imaging System with 30-MHz RMV-707b scanning head 
(VisualSonics). Pulmonary acceleration time (PAT) and PAT as a fraction of 
ejection time (ET) were measured from the pulse-wave Doppler recordings of the 
PA blood flow as previously described 148. 
For assessment of right ventricular hypertrophy the ventricles were 
excised and weighed. The weight ratio of the right ventricle to the left ventricle 
plus septum was calculated as index of RV hypertrophy. 
Right ventricular pressure was measured with a high-fidelity pressure 
catheter inserted in the right ventricle via cannulation of the right jugular vein, to 
monitor the development of pulmonary hypertension. Briefly, mice were 
anaesthetized with an intraperitoneal injection of 100 µl of Ketamine (75mg/kg) 
and Xylazine (10 mg/kg) and kept recumbent on a heating pad at 39°C, to 
maintain body temperature during the surgical procedure. A 1.5 cm incision was 
performed vertically in the central neck area. The right jugular vein was gently 
isolated, free of connective tissue, and blood flow temporarily occluded with a 6-0 
silk suture. A 1.2F Mikro-tip® pressure catheter transducer (Model SPR-1000, 
Millar Instruments) was inserted in the jugular vein by puncturing the vein with a 
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27 G needle bended at 90°, and gently advanced into the right ventricle. 
Pressure waveforms were monitored in real time with the PowerLab Chart 8 data 
acquisition system (ADInstruments) and 10 min of stable pressure recordings 
were acquired for each mouse. RV pressures were calculated by averaging at 
least 60 cardiac cycles for each mouse. 
 
Tissue Collection, Histology and Immunohistochemistry 
The left lung was fixed by tracheal perfusion either with 4% 
paraformaldehyde or 50% OCT in PBS. Skin was fixed in 4% paraformaldehyde. 
5-µm sections were used for staining. 
For histology, paraffin sections were stained with Gomori trichrome 
(Chromaview). Collagen fibers were stained blue, nuclei were stained black, and 
the background was stained red.  
For immunohistochemistry with active β-catenin antibody (mouse-on-
mouse) sections were blocked with unconjugated Fab fragment (Jackson 
ImmunoResearch) for 1h. Slides were incubated with primary active β-catenin 
antibody (1:100, clone 8E7, Millipore) over night at 4°C and for 30min with the 
secondary antibody, a biotinylated-Fab fragment (Jackson ImmunoResearch). 
For immunohistochemistry with all other antibodies, slides were deparafinized 
and rehydrated and subjected to a 1 min antigen retrieval treatment in a pressure 
cooker with an antigen unmasking solution (Vector Laboratories). Endogenous 
peroxidase was blocked by incubating the section in 3% hydrogen peroxide for 
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20 min, followed by an incubation with 0.15 M glycine for 15 min., blocked in 3% 
BSA, and incubated with antibody against nitrotyrosine (EMD Millipore), aSMA ( 
NB600-531, Novus Biologicals), ERG (Biocare Medical, Concord, CA), vWF 
(Dako, Carpinteria, CA), MAC3 and CD45 (BD Biosciences, San Jose, CA) 
overnight at 4 degrees C and for 30 min with the secondary antibody (1:200 for 
biotynolated antibodies, 1:200 for fluorescent antibodies). A solution containing 
avidin:biotin:peroxidase complexes was applied to the sections with biotynolated 
antibody subsequently. Immunoreactivity was visualized with diaminobenzidine 
(Vector Laboratories), and the sections were counterstained with hematoxylin. 
For immunofluorescence slides were mounted with Vectashield with DAPI 
(Vector, H-1200) and imaged using an Olympus confocal microscope. 
For all immunofluorescence staining of frozen tissue, lung samples were 
directly embedded in O.C.T. (Thermo Fisher) compound, flash frozen, and stored 
at -80°C. Staining was performed on 5 µm cryosections of mouse lung. In brief, 
slides were blocked with a blocking solution (3% BSA (Sigma-Aldrich), and 0.3% 
Triton X-100 in PBS) for 2 hours. After washing, tissue sections were incubated 
at 4°C overnight with primary antibodies: ERG (clone EPR3863, Abcam), CD31 
(clone SZ31, Dianova), vWF (Dako), CD45 (eBioscience), MAC3 (BD 
Biosciences), αSMA (Lab Vision/NeoMarkers) and nitrotyrosine (EMD Millipore). 
Secondary antibodies conjugated with Alexa 488 and Alexa 590 were used. 
Coverslips were mounted by using Vectashield with DAPI (Vector Laboratories).  
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Pulmonary Vascular Morphometry and Immune Cells Counting 
Peripheral pulmonary arteries ranging in 20 to 70 mm in size were 
counted in at least four fields at 20x magnification with a Zeiss Axiovert-35 
inverted microscope. Counted vessels were categorized into non-muscularized, 
partially muscularized (1% to 74% of medial layer has positive αSMA staining), or 
fully muscularized (75% to 100% of medial layer has positive αSMA staining). 
Percentages of vessels in each category were calculated by dividing the total 
number of vessels in each category by the total number of vessels counted in the 
field. For the quantification of immune cells, ImageJ (NIH, Bethesda, MD) was 
used to count DAPI positive nuclei (total number of cells) and MAC3 or CD45 
positive cells from at least 5 fields of view per sample. Tissue infiltration by cells 
was calculated as a fraction of MAC3 or CD45 positive cells over total number of 
cells (DAPI positive). 
 
Human samples  
Lung samples were obtained from SSc-PAH and iPAH patients who 
underwent lung transplantation and control subjects at the University of 
Pittsburgh Medical Center, under a protocol approved by the Institutional Review 
Board. 
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Cell Culture 
Human pulmonary artery endothelial cells (HPAECs) were purchased from 
Lonza. Lung fibroblasts were obtained from patients with SSc and lung vascular 
smooth muscle cells from PH patients who underwent lung transplantation at the 
University of Pittsburgh Medical Center, under a protocol approved by the 
Institutional Review Board. Control lung fibroblasts were obtained from organ 
donors whose lungs were not used for lung transplantation. IMR90 fetal lung 
fibroblasts were purchased from ATCC. Skin fibroblasts were obtained by skin 
biopsy from the affected areas (dorsal forearm) of patients with diffuse cutaneous 
SSc (three females and two males; median age 45 y, range 30–62 y). Control 
fibroblasts were obtained by skin biopsy of a healthy donor (within several days 
of SSc biopsy); these were matched with each SSc patient for age, race, gender, 
and biopsy site and were processed in parallel. Explant tissue was dissociated 
enzymatically by 0.25% collagenase type I (Sigma, St. Louis, MO) and 0.05% 
DNase (Sigma) in Dulbecco's modified Eagle's medium (DMEM) with 20% fetal 
bovine serum (FBS) (GibcoBRL, Grand Island, NY). Cells were grown in DMEM 
supplemented with 10% FBS. The cells were used at passage number 5 to 8 for 
all experiments. For hypoxic conditions cells were incubated at 1-2.5% O2 for 
indicated period of time. Poly(I:C) was from Invivogen, interferon beta 1a was 
from PBL Assay Science, B18R was from eBioscience, and the TLR3/complex 
inhibitor was from EMD Millipore.  
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Quantitative RT-PCR  
For RNA isolation the right lung was tied off and saved in RNAlater (Life 
Technologies). Total lung RNA was isolated by using the RNeasy Tissue Mini Kit 
(Qiagen). Total RNA from cultured cells was isolated using the TRI Reagent 
(MRC Inc.) and then reverse transcribed with random hexamers by using the 
Transcriptor First Strand Complementary DNA Synthesis kit (Roche Applied 
Science) according to the manufacturer's protocol. Real-time PCR assays were 
performed by using the StepOnePlus Real-Time PCR system (Applied 
Biosystems) using SYBR® Green PCR Master Mix (Applied Biosystems) or 
TaqMan® (Invitrogen). The mouse primers are listed in Table 2 and human 
primers in Table 3. Relative change in the levels of genes of interest was 
determined by the 2-ΔΔCT method using house keeping genes. 
 
Microarray analysis 
Microarray analysis was performed at The Boston University Microarray 
Core Facility. Affymetrix CEL files were normalized to produce gene-level 
expression values using the implementation of the Robust Multiarray Average 
(RMA) 149 in the affy package (version 1.36.1) 150 included within in the 
Bioconductor software suite (version 2.12) 151 and an Entrez Gene-specific 
probeset mapping from BrainArray (version 16.0.0) 152. RLE and NUSE quality 
metrics were computed using the affyPLM Bioconductor package (version 
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1.34.0) 153. All microarray analyses were performed using the R environment for 
statistical computing (version 2.15.1). 
Link to GEO- deposited data: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=idkrsmsqrlsrzqx&acc=GSE
83641 
 
Immunoblotting  
Cells were collected and washed with PBS. Cell pellets were suspended 
in lysis buffer containing 20 mM Tris-HCl, pH 7.5, 15 mM NaCl, 1 mM EDTA, 
1mM EGTA, 1% Triton X-100, 2.5mM sodium pyrophosphate and 1mM 
glycerophosphate with freshly added phosphatase inhibitors and a protease 
inhibitor mixture (Sigma-Aldrich). Protein concentration was quantified using the 
BCA Protein assay kit (Thermo Fisher Scientific). For nuclear extraction, the NE-
PER nuclear and cytoplasmic extraction kit (Thermo Fisher Scientific) was used 
according to the manufacturer’s instructions. Protein samples were subjected to 
SDS-PAGE electrophoresis and then transferred to the nitrocellulose 
membranes. Membranes were blocked with nonfat dry milk in TBST and then 
probed overnight with primary antibodies (1:1000): pSMAD2/3, SMAD2/3, 
pSMAD1/5, SMAD1/5, pSTAT3, STAT3, pcJUN, and cJUN from Cell Signaling, 
Lamin A/C, Sp1, and CTGF from Santa Cruz Biotechnology, Col I from Southern 
Biotech, β-catenin from Abcam, and HO-1 from Enzo. 
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Blots were incubated for 1 h in the appropriate horseradish peroxidase-coupled 
secondary antibodies (1:1000, Santa Cruz Biotechnology) and developed using 
the Chemiluminescent detection kit (Thermo Fisher Scientific). Band intensities 
were determined by densitometric analysis with ImageJ software.  
 
Staining for ROS 
HPAECs treated with GATA6 siRNA or SCR siRNA as well as ECs 
isolated from GATA6 CKO or WT mouse lungs were grown on coverslips and 
stained with CellROX, MitoSOX and NucBlue (Life Technologies) according to 
manufacturer protocol. Cells were categorized based on the signal positivity and 
counted in ImageJ software.  
 
GPX and SOD activity assays 
Enzymatic assay kits were bought from Cayman and used according to 
manufacturer protocol.  
 
Chromatin Immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed as previously 
described 148 using ChIP grade SP1 antibody (EMD Millipore) and ERG antibody 
(clone EPR3863, Abcam). Real time qPCR was performed in triplicate using 
specific primers for the human COL1A2 gene promoter (Forward 
GCGGAGGTATGCAGACAACG, Reverse GGGCTGGCTTCTTAAATTG) and 
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primers for the human IFNB1 gene promoter (Forward-
AGGAAAACTGAAAGGGAGAAGTG, Reverse-
GAAAGGTTGCAGTTAGAATGTCC). Open reading frame (ORF) primers were 
used as a negative control. The amount of immunoprecipitated DNA (percent 
recovery) was calculated from a standard curve generated with the serial 
dilutions of input chromatin.  
 
siRNA Transient Transfections 
Cells were transfected with siRNA specific to human GATA6, NRF2, ERG, 
FLI1, YAP/TAZ (ON-TARGETplus SMART pool; Thermo Fisher Scientific Inc.), 
human βTRCP (Santa Cruz Biotechnology) or negative control siRNA (Qiagen) 
for the duration of 48h at the concentration of 10 nM using Lipofectamine 
RNAiMAX Transfection Reagent (Thermo Fisher Scientific) according to the 
manufacturer's protocol.  
 
Plasmid Transient Transfections and Luciferase Assay 
A luciferase reporter driven by −353 to +58 fragment (representing the 
wildtype Sp1 binding sites) of the human COL1A2 promoter was described 
previously 154. For the NFκB activity reporter we used Ready-To-Glow™ 
NFkappaB Secreted Luciferase Reporter System (Clontech). Transient 
transfections with plasmids containing the reporters were performed in fibroblasts 
or HPAECs seeded into 6-well plates using Fugene6 (Roche Applied Science) 
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according to the manufacturer's instructions. The cells were harvested and 
assayed for luciferase reporter activity using the Thermo Scientific Pierce Firefly 
Luciferase Glow Assay Kit (Thermo Fisher) or the Ready-To-Glow Secreted 
Luciferase Assay (Clontech) according to the manufacturer's instructions. 
Promoter/reporter plasmids were co-transfected with pCMV-βGal (Clontech) to 
adjust for differences in transfection efficiencies between samples.  
 
Statistical analysis 
Prism 5 (GraphPad) was used for all analyses. Values are presented as 
means ± SD. Differences between more than two groups were compared with 
ANOVA with a post hoc Tukey test, α=0.05. Two sided student t test was used 
for comparing 2 groups, α=0.05. 
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Table 2 Mouse qPCR primers 
Gene 
name Forward primer Reverse primer 
aSma CCCACCCAGAGTGGAGAA ACATAGCTGGAGCAGCGTCT 
B2MG TCGCTCGGTGACCCTAGTCTTT ATGTTCGGCTTCCCATTCTCC 
Ccl2 CATCCACGTGTTGGCTCA GATCATCTTGCTGGTGAATGAGT 
Col1a1 GCCAAGAAGACATCCCTGAAG TGTGGCAGATACAGATCAAGC 
Col1a2 GCCACCATTGATAGTCTCTCC CACCCCAGCGAAGAACTCATA 
Col5a1 GGACTAGTCCGCTTTCCCTGTCAACTTG 
GTGGTCACTGCGGCTGAGGAA
CTTC 
Ctgf CTGCAGACTGGAGAAGCAGA GATGCACTTTTTGCCCTTCTT 
Cx3cl1 AAGATGACCTCACGAATCCCAGT GTCTGTGCTGTGTCGTCTCC 
Et-1  CTGCTGTTCGTGACTTTCCA TCTGCACTCCATTCTCAGCTC 
Gata6 CCAGCAGGACCCTTCGAAAC CGCATGCATTGCACAGGTAAT 
Gpx1 TTCGGACACCAGGAGAATGG TAAAGAGCGGGTGAGCCTTC 
Gpx2 TCGGACATCAGGAGAACTGTC TGCCCATTGACGTCACACTT 
Gpx3 TTCCTGAAGAACTCCTGCCCT CCAGCGGATGTCATGGATCT 
Gpx4 CCAAAGTCCTAGGAAACGCCC GGGATGCACACAAGCCCAG 
Gpx5 CCTTCTTGAAGCGTTCTTGTCC TCCAGCGGATGTCATGGACT 
Gpx5 GTCACGGTTTTGGGCTTTCC GCCTGGACGCACATACTTGA 
Gpx7 ACCGTGGCTCGGTTTCCC CAAACTGGTTGCAAGGGAAGG 
Gsr TGGCACTTGCGTGAATGTTG TGTTCAGGCGGCTCACATAG 
Gss CACTGGGTCGTACCGAAGC ATCCCAACTCGCTCGTTGTC 
Gstm4 AGTCAAAGTTGCTCACACCG CGGTCATAGTCAGGAGCGTC 
Gstt2 CTTGTGTCGCTACCGGCAAT CTCATGTGCTGCCCTTTGAGT 
Ho-1 AGGCTAAGACCGCCTTCCT TGTGTTCCTCTGTCAGCATCA 
Icam-1  CCCACGCTACCTCTGCTC  GATGGATACCTGAGCATCACC  
Ifit2 GTAGGGGTTACATCCGGCAC TCTGTGCAGCACCTCTAAGTC 
Ifnb1 CTGGCTTCCATCATGAACAA AGAGGGCTGTGGTGGAGAA 
Il-6  GCTACCAAACTGGATATAATCAGGA  CCAGGTAGCTATGGTACTCCAGAA  
Nox4 CCCTAAACGTTCTACTTTTCTGGA TGCTCTGCTTAAACACAATCCT 
Osm  TGCTCCAACTCTTCCTCTCAG  CAGGTTTTGGAGGCGGATA  
Pai-1  AGGATCGAGGTAAACGAGAGC  GCGGGCTGAGATGACAAA  
Sod2 AGGAGAGTTGCTGGAGGCTA AGCGGAATAAGGCCTGTTGTT 
Tgf-β1 GCAGCACGTGGAGCTGTA CAGCCGGTTGCTGAGGTA 
Tgf-β2 CCTTCTTCCCCTCCGAAAC AGAGCACCTGGGACTGTCTG 
Tgf-β3 AAGAAGCGGGCTTTGGAC CGCACACAGCAGTTCTCC 
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Table 3 Human qPCR primers 
 
Gene 
name Forward primer Reverse primer 
APLN CCCAAGGAGCAGCATGAATCT GTCTTCCAGCCCATTCCCATC 
CCL2 AGTCTCTGCCGCCCTTCT GTGACTGGGGCATTGATTG 
COL1A1 TGTTCAGCTTTGGACCTCCG CCGTTCTGTACGCAGGTGATTG 
COL1A2 GATGTTGAACTTGTTGCTGAGG TCTTTCCCCATTCATTTGTTCTT 
CTGF TTGCGAAGCTGACTCGGAAGAGAA 
AGCTCGGTATGTCTTCATGCT
GGT 
CX3CL1 CCACCTTCTGCCATCTGAC  ATGTTGCATTTCGTCACACC 
ET-1  GCTCGTCCCTGATGGATAAA CCATACGGAACAACGTGCT  
FABP4 TCACTGCAGATGACAGGAAAGT 
CATCCCATTTCTGCACATGTAC
C 
GATA6 TTGTGGACTCTACATGAAACTCCA 
TTATGTTCTTAGGTTTTCGTTT
CCTG  
GPX1 TATCGAGAATGTGGCGTCCC TCTTGGCGTTCTCCTGATGC 
GPX3 CGGATTGGTCACACCCGAG ACTTCTCTTGTCCCCGGCT 
GPX7 CTTTAACGTGCTCGCCTTCC ATGAGACACTGTAGGTGCGG 
HAS2 TCATGTACACAGCCTTCAGAGC 
GATGAGGCTGGGTCAAGCATA
G 
HO-1 GGCAGAGGGTGATAGAAGAGG AGCTCCTGCAACTCCTCAAA 
ICAM1 GGGAGCTTCGTGTCCTGTAT ACTTGAGCTCGGGCAATG 
IFNB1 CTCCTCCAAATTGCTCTCCTGT AAGAGCTGTAGTGGAGAAGCAC 
IL-6 ATGAGGAGACTTGCCTGGTG GGGTCAGGGGTGGTTATTGC 
MMP1 TCTGGGGTGTGGTGTCTCA  GCCTCCCATCATTCTTCAGGTT  
NOX4 GCTGACGTTGCATGTTTCAG CGGGAGGGTGGGTATCTAA 
NRF2 AGTGGATCTGCCAACTACTC CATCTACAAACGGGAATGTCTG 
OSM GGTACTGCTCACACAGAGGAC TATAGGGGTCCAGGAGTCTGC 
PAI-1  CCCAGCTCATCAGCCACT GAGGTCGACTTCAGTCTCCAG  
PDGFB AGATCGAGATTGTGCGGAAGA GCTGCCACTGTCTCACACTTG 
TGFβ1 GCAGCACGTGGAGCTGTA CAGCCGGTTGCTGAGGTA 
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CHAPTER 3 - ENDOTHELIAL GATA6 DEFICIENCY PROMOTES OXIDATIVE 
AND ER STRESS IN LUNG 
The transcription factor GATA6 is highly transcribed in normal pulmonary 
vasculature, including endothelial cells and smooth muscle cells, but markedly 
less so in both SSc-PAH and idiopathic PAH (iPAH) lungs. Genetically modified 
mice that lack GATA6 in endothelial cells spontaneously develop PAH, 
suggesting that downregulation of GATA6 is an early and key event that leads to 
endothelial dysfunction and the development of PAH. Given the important role of 
oxidative and endoplasmic reticulum (ER) stress pathways, as well as 
mitochondrial dysfunction in pathogenesis of endothelial injury, we aimed to test 
the hypothesis that GATA6 deficiency in endothelium contributes to imbalance in 
redox, mitochondria and ER homeostasis. 
Introduction 
Role of endothelial GATA6 deficiency in promoting PAH 
The GATA family of transcription factors in mammals includes six family 
members with two highly conserved tandem zinc fingers that recognize and bind 
to the DNA motif (G/A)GATA(A/T) 155. GATA 1, 2 and 3 are essential in 
developmental processes orchestrating hematopoietic stem cell differentiation, 
whereas GATA 4, 5 and 6 function in development of mesoderm- and endoderm-
derived organs including the heart, gastrointestinal tract and lungs 156,157. In adult 
  
45 
tissues GATA factors are important for maintaining cells in a differentiated state, 
therefore contributing to tissue homeostasis 158.  
GATA6 is ubiquitously expressed in adult human organs including the 
heart, lungs, liver, pancreas, spleen, ovary and the small intestine 159. A cell type 
specific function for GATA6 has been well studied in vascular smooth muscle 
cells (VSMC), where it is responsible for maintaining the quiescent, non-
proliferative state. Loss of GATA6 in VSMC has been observed in several animal 
models of vascular injury. Additionally, vascular GATA6 is significantly reduced in 
spontaneously hypertensive rats, and the pharmacological amelioration of the 
disease correlates with normalization of the GATA6 expression levels 160-162.  
In endothelium, GATA6 has been shown to regulate angiogenesis and 
endothelial cell survival 163. Our group has previously demonstrated that 
endothelial depletion of GATA6 in mice leads to spontaneous development of 
PAH and augmented hypoxia-induced vascular remodeling. Importantly, GATA6 
is reduced in pulmonary vasculature of SSc-PAH and iPAH patients. 
Mechanistically, loss of GATA6 in human pulmonary artery endothelial cells 
(HPAECs) causes an increase in pro-inflammatory and PAH-related genes 148. 
In summary, there is a strong correlation between loss of endothelial GATA6 
expression and increased inflammation and vascular remodeling in lung. 
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Endothelial mitochondrial damage, oxidative and ER stress in promoting PAH 
Mitochondrial volume in endothelial cells is relatively low and does not 
contribute to cellular energetic processes (oxidative phosphorylation) to the same 
degree as in other high energy demanding cell types 164. Mitochondria are 
therefore considered to primarily have a regulatory role in ECs. Endothelial 
mitochondria predominantly serve as sensors that transduce environmental 
signals including shear stress, inflammation and hypoxia 165 via reactive oxygen 
species (ROS)  intermediates. 166. The known sources of mitochondrial ROS 
include complexes I and III, NAPDH oxidase 4 (NOX4), monoamine oxidase 
(MAO), the growth factor adaptor protein p66Shc and mitochondrial ATP-
sensitive potassium channel (mitoKATP) 167 . Interestingly, ROS produced in 
cytoplasm by NOX and uncoupled eNOS, as well as ROS derived from other 
mitochondria, can induce mitochondrial ROS generation in a process called 
ROS-induced ROS release 168.  
Hydrogen peroxide is a mitochondrial ROS primarily used for signaling, 
and has been shown to regulate autophagy, inflammation and hypoxic response 
169. Superoxide, on the other hand, is a highly reactive and damaging 
mitochondrial ROS, which can oxidize mitochondrial DNA (mtDNA), proteins and 
lipids. Presence of damaged mtDNA has been implicated in several vascular 
disorders, including atherosclerosis and coronary artery disease 170,171. 
Additionally, accumulation of oxidized, misfolded proteins in mitochondria can 
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overwhelm physiological clearance by mitophagy and lead to the induction of ER 
stress. 
To defend against superoxide-mediated damage, mitochondria utilize the 
SOD2 enzyme to convert superoxide to hydrogen peroxide. Levels of hydrogen 
peroxide, which in excess also promotes oxidative stress, are further regulated 
by cytoplasmic and mitochondrial catalases and peroxidases including 
glutathione peroxidase (GPX) 172. Consistent with their protective role in 
endothelial cells, depletion of these enzymes in animal models leads to 
increased mitochondrial damage, endothelial dysfunction and susceptibility to 
vascular damage 173,174. Imbalance in redox homeostasis plays a major role in 
PAH pathogenesis, since oxidative stress is known to promote endothelial 
dysfunction, SMC proliferation and activation of adventitial fibroblasts 57,98,172,175. 
The mitochondria and the ER are in close proximity within the cell and 
cooperatively regulate endothelial function through calcium trafficking; therefore 
perturbations in either of these systems can cause endothelial dysfunction 176,177. 
Loss of ER homeostasis mediated by oxidative stress can trigger ER stress and 
unfolded protein response (UPR), and prolonged, unresolved ER stress 
inevitably leads to cell death 178,179. Importantly, ER stress has been linked to 
endothelial dysfunction and PAH in humans 180,181.  
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Results 
SSc-PAH patients and GATA6 CKO mice have elevated markers of oxidative 
and ER stress in lungs 
To determine whether loss of endothelial GATA6 promotes oxidative 
stress, we stained lungs of SSc-PAH patients and GATA6 endothelial specific 
(VE Cadherin Cre) knock out mice (CKO), with nitrotyrosine, a marker of 
oxidative damage (Figure 6). Compared to healthy controls, the lungs of SSc-
PAH patients had increased nitrotyrosine staining, which appeared more 
concentrated around vessels (black arrows). Similarly, lung sections of GATA6 
CKO mice showed increased nitrotyrosine staining in comparison to wild type 
littermates (WT), although staining was more diffuse throughout the tissue and 
signal intensity was heterogeneous between mice (GATA6 CKO1 vs. GATA6 
CKO2). 
Oxidative stress induces ER stress 182. Therefore, we next examined the 
expression of BiP and CHOP, important factors in the ER stress response 
(Figure 7). Similarly to nitrotyrosine, expression of both ER markers was 
upregulated in endothelium of lungs in SSc-PAH patients as compared to HC 
lungs. GATA6 CKO mice also had elevated levels of BiP and CHOP, although 
the staining was present both in endothelial cells and other cell types throughout 
the lung. To clarify this result we tested the gene expression of BiP and CHOP in 
GATA6 CKO whole lungs, which confirmed upregulation of both factors in 
GATA6 deficient mice (Figure 7 upper panel). 
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Figure 6 PAH patients and GATA6 CKO mice have elevated oxidative stress in 
lungs. Nitrotyrosine staining of paraffin embedded lung sections from healthy 
control human (HC), SSc-PAH patient, wild type mice (WT) and two GATA6 
endothelial knockout mice (GATA6 CKO1 and 2). Arrows are indicating vessels. 
Representative pictures are shown. 
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Figure 7 PAH patients and GATA6 CKO mice have elevated ER stress in lungs.  
Upper panel shows qPCR analysis of BiP and CHOP gene expression in lung 
tissue from WT and GATA6 CKO mice. Lower panel shows representative 
pictures of immunostaining for BiP and CHOP, markers of ER stress in lung 
samples from healthy control (HC), SSc-PAH patient , wild type mouse (WT) and 
GATA6 CKO mouse. 
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Downregulation of GATA6 induces ROS production and impairs anti-oxidative 
pathways both in vitro and in vivo 
To directly investigate the correlation between downregulation of GATA6 
and increased oxidative stress we measured ROS levels in GATA6-silenced 
human pulmonary artery endothelial cells (HPAECs) and GATA6 CKO 
pulmonary endothelial cells (ECs). siRNA-mediated downregulation of GATA6 in 
HPAECs caused a dramatic increase in total and mitochondrial ROS, as 
visualized by CellROX (total cellular ROS marker) and MitoSOX (mitochondrial 
ROS marker) staining (Figure 8 upper panel). Similarly, a significantly higher 
number of pulmonary ECs isolated from GATA6 CKO mice were positive for total 
and mitochondrial ROS (Figure 8 lower panel). 
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Figure 8 Downregulation of GATA6 results in elevated ROS levels in HPAECs 
and GATA6 CKO pulmonary ECs. Staining for total ROS (CellROX) and 
mitochondrial ROS (MitoSOX) in HPAECs (upper panel) and mouse pulmonary 
ECs from wild type (WT) and endothelial GATA6 knockout (G6 CKO) mice 
(middle panel). Quantification of positive cells measured from 5 fields of view per 
mouse (lower panel). n=3 mice per group. Data shown as mean ±SD. 
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We next examined the mechanism of ROS upregulation upon loss of 
GATA6. Increased ROS can originate from either increased ROS production (by 
NOX enzymes) or insufficient ROS clearance (by SOD2, GPXs, glutathione S 
transferase (GST) and glutathione synthetase (GSS). Gene expression 
measured by qPCR in GATA6 silenced HPAECs and pulmonary ECs from 
GATA6 CKO mice showed slight upregulation of NOX isoforms and significant 
downregulation of SOD2, GPXs and GSTT2 (Figure 9). The HPAECs had 
undetectable mRNA levels of NOX1 and NOX2 as well as GSS, GPX2, 5 and 6. 
We also confirmed, in physiologically relevant enzyme activity assays, that 
activities of SOD and GPX were significantly reduced in GATA6 silenced 
HPAECs (p<0.05 for SOD and p<0.001 for GPX) and GATA6 CKO whole lung 
extracts (p<0.01 for SOD and p<0.01 for GPX) (Figure 10). 
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Figure 9 Anti-oxidative enzyme expression is downregulated in GATA6-depleted 
HPAECs and lungs of GATA6 CKO mice. Relative mRNA levels in GATA6 
siRNA treated HPAECs (left panel) and pulmonary ECs from GATA6 CKO mice 
(right panel) as measured by qPCR normalized to control cells (scrambled 
siRNA). n=4 independent experiments for HPAECs, n=4 mice per group. Data 
shown as mean ±SD. *P<0.05, **P<0.01, ***P<0.001.   
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Figure 10 GPX and SOD enzyme activities are decreased in the absence of 
GATA6. Enzymatic activity assays for SOD and GPX were performed on protein 
lysates from HPAECs treated with scrambled (SCR) siRNA or GATA6 (G6) 
siRNA, as well as HPAECs from whole lungs from wild type (WT) or GATA6 (G6) 
CKO mice. n=3 independent experiments for HPAECs, n=5 mice/group. Data 
shown as mean ±SD. *P<0.05, **P<0.01, ***P<0.001.   
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Discussion 
Loss of endothelial GATA6 contributes to endothelial dysfunction and 
vascular remodeling via several pathways. Our previously published research 
showed that pulmonary vasculature in SSc-PAH had significantly reduced levels 
of GATA6, and endothelial GATA6 knockout mice spontaneously developed PAH 
through increased pro-inflammatory and HIF genes expression 148. In this study 
we demonstrate that GATA6 depletion in endothelium induces oxidative and ER 
stress, resembling the pathological changes in SSc-PAH patients. The level of 
oxidative damage, as indicated by nitrotyrosine immunostaining in lung, was 
heterogeneous in GATA6 CKO mice and seemed to localize to all cellular 
structures in the lung. The mice used in this study were approximately 8 weeks 
old, at which point the oxidative stress, which originated in endothelial cells, 
might have affected the rest of the tissue. 
Downregulation of GATA6 both in vitro in HPAECs and in vivo in GATA6 
CKO mice resulted in increased levels of total and mitochondrial ROS. 
Mechanistically, loss of GATA6 caused transcriptional downregulation of genes 
important for ROS clearance including SOD2 and GPXs, although GATA6 did not 
directly bind to the promoters of those genes (data not shown). Importantly, 
activity of SOD and GPX enzymes was significantly reduced in lung tissues 
derived from CKO mice and HPAECs with GATA6 knockdown, implying the 
presence of an additional factor in the regulatory mechanisms.  
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These results suggest that GATA6-dependent loss of anti-oxidative 
capacity in endothelial cells might be crucial in initiating endothelial damage and 
dysfunction, as well as mediating progression of pathological events in PAH. 
Consistent with this idea, other groups have found that epigenetic attenuation of 
SOD2 contributes to PAH by promoting SMC proliferation, while deficiency of 
GPX1 or SOD2 in apoE-deficient mice aggravates endothelial dysfunction and 
atherosclerotic lesion progression 173,174,183 . 
Our data demonstrate, for the first time, the important role of GATA6 in 
regulating cellular redox balance and interconnected ER homeostasis in 
pulmonary endothelium. GATA6 regulates a diverse and complex array of genes 
that are collectively important for the maintenance of endothelial homeostasis. 
Therefore, alterations in levels of GATA6 might have a profound effect on the 
function of endothelium, indicating that loss of GATA6 may play an important role 
in promoting vascular damage. 
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CHAPTER 4 – SYNERGISTIC ROLE OF ENDOTHELIAL ERG AND FLI1 IN 
MEDIATING PULMONARY VASCULAR HOMEOSTASIS 
Endothelial cell activation underlies many vascular diseases, including 
pulmonary arterial hypertension (PAH). Several members of the E-twenty six 
(ETS) family of transcription factors are important regulators of the gene network 
governing endothelial homeostasis, and their aberrant expression is associated 
with pathological angiogenesis. The goal of this study was to determine whether 
deficiencies of the ETS family member FLI1 and its closest homolog ERG are 
associated with PAH. 
Introduction 
ETS is a large family of transcription factors consisting of almost 30 
members with 27 and 26 ETS genes identified in the human and mouse, 
respectively. Depending on a factor, interaction with other regulatory proteins as 
well as posttranslational modifications, ETS transcription factors can be either 
repressors and activators. The highly conserved DNA-binding domain (ETS 
domain) is an 85 amino acid long winged helix-turn-helix motif consisting of three 
alpha-helices and four anti-parallel beta-sheets. The third alpha helix is thought 
to be primarily responsible for DNA-binding specificity, which is a sequence motif 
5’-GGA(A/T)-3’ 184.  
The biological function of ETS family proteins is regulation of apoptosis, 
cell differentiation, and proliferation in multiple different cell types. Deregulation of 
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some ETS proteins has been also observed in various cancers, in particular 
leukemias 185. Despite their wide range of action, the predominant role of ETS is 
believed to be maintenance of vascular integrity and homeostasis through 
regulation of endothelial cell gene expression 186. In SSc patients a deregulation 
of ETS family member FLI1 has been demonstrated and investigated both in vitro 
and in animal models 187.  
The role of FLI1 in regulating endothelial cell differentiation during vessel 
maturation and the maintenance of vascular homeostasis has been extensively 
studied. Mice with targeted deletion of Fli1 gene die at E11.5 days as a result of 
cranial and spinal hemorrhages 145. FLI1 is expressed in skin microvascular 
endothelium of adults during health, however it is markedly downregulated in 
affected skin of SSc patients 76. FLI1 in endothelial cells positively regulates 
expression of genes responsible for cell-cell contact: VECadherin, CD31/platelet-
endothelial cell adhesion molecule (PECAM)-1 and type IV collagen 188. 
Therefore depletion of FLI1 leads to compromised vascular permeability, which 
manifests as disorganized vascular network, loss of vessel integrity, impaired 
development of vessel basal membrane and decreased coverage of perivascular 
pericytes 188. Importantly, all these pathological features are found in the affected 
skin of SSc patients. Additionally FLI1 in experimental models regulates genes 
responsible for angiogenesis including the following CCN1, CXCL5, cathepsin B 
and cathepsin V, consistent with a non-sufficient neoangiogenesis in SSc 
patients 189-191. 
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ERG, the closest FLI1 homolog, is the most highly expressed ETS 
member in resting endothelial cells 192-194. Its role in vascular development is 
based on a regulation of endothelial homeostasis, survival and differentiation 195-
197. Mice with targeted deletion of Erg gene die at E11.5 as a result of defects in 
hematopoiesis and endothelial Erg expression is required for embryogenesis and 
vascular integrity 146,197.  Downregulation of ERG expression in human umbical 
vein endothelial cells (HUVECs) results in loss of cell-cell junction and induces 
apoptosis. Downregulated genes include VE-Cadherin, SPARC, THBS1, VWF, 
RHOJ, ICAM2, CLDN5 and CDH5, which are involved in various vascular 
processes 198-200. Recent studies in HUVECs show that ERG also serves as a 
repressor for many pro-inflammatory genes (NFkB, IL-8) which might contribute 
to keeping endothelial cells in quiescent state 201,202. Interestingly, in vivo studies 
show that pro-inflammatory stimuli like lipopoisacharade (LPS) or TNFα 
treatments downregulate endothelial ERG expression 198,202. 
 
Results 
Endothelial ERG is reduced in lungs of PAH patients and in lungs of chronic 
hypoxic mice 
Downregulation of endothelial ERG has been previously shown in injured 
vasculature 198,202,203. To evaluate the levels of endothelial ERG in diseased 
pulmonary vasculature in humans, lung sections from iPAH, SSc-PAH and 
healthy control (HC) were immunostained with endothelial marker van Willebrand 
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Factor (vWF) and ERG. As shown in Figure 11, the endothelium in HC lung had 
high levels of nuclear ERG, as compared to significantly lower levels or even 
complete loss of ERG in the endothelium of iPAH and SSc-PAH patients. When 
quantified, the differences in vessel numbers with high and medium ERG levels 
between HC and PAH were statistically significant (Figure 11 B). To demonstrate 
that loss of endothelial ERG is a general phenomenon occurring upon vascular 
injury, we assessed ERG levels in lungs of chronically hypoxic mice. Chronic 
hypoxia is a known factor that induces pulmonary vascular defects, including 
endothelial dysfunction and perivascular inflammation 204. Immunostaining shown 
in Figure 11 C demonstrates ERG nuclear localization in endothelial cells (CD31 
positive) under normoxic conditions; however, in hypoxic conditions, nuclear 
ERG is visibly depleted from endothelial cells. The statistical significance of this 
observation was verified by quantification of ERG positive and negative 
endothelial cell nuclei in normoxic and hypoxic mice (Figure 11 D).  
In conclusion endothelial ERG is downregulated in lungs of human 
subjects with systemic and pulmonary vascular disorders as well as in a hypoxic 
mice model. 
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Figure 11 Endothelial ERG is downregulated in lungs of PAH patients and in 
chronically hypoxic mice. (A) Paraffin embedded lung sections from healthy 
control (HC), idiopathic PAH (iPAH) and SSc-associated PAH (SSc) were 
immunostained with vWF and ERG antibodies. (B) Vessels from 5 fields of view 
were categorized based on endothelial nuclear ERG signal as high, medium or 
low. n=3 for HC, n=5 for iPAH/SSc. (C) C57BL/6 mice were kept in hypoxia 
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(10%O2) or normoxia (21%O2) for 21 days. Frozen lung sections were 
immunostained with CD31 and ERG antibodies. (D) Endothelial nuclei from 5 
fields of view were counted and categorized as ERG positive (white arrowhead) 
or ERG negative (yellow arrowhead). n=4 mice per group. Data shown as 
mean±SD. One way ANOVA followed by Tukey’s multiple comparison and a 
student t-test were used for statistical analysis. *P<0.05, **P<0.01, ***P<0.001   
 
FLI1 and ERG synergistically regulate interferon genes in human pulmonary 
artery endothelial cells (HPAECs) 
FLI1 is the closest homologue of ERG and, similar to ERG, is known to 
regulate genes that sustain endothelial homeostasis. We therefore asked if there 
is a transcriptional synergy between those two factors. We addressed this 
question by performing FLI1/ERG double siRNA-mediated knockdown in human 
pulmonary artery endothelial cells (HPAECs) for 48 h followed by microarray 
analysis of gene expression. The top 20 most significantly upregulated genes are 
listed in Table 4 and top 20 downregulated genes in Table 5. As predicted, the 
list of downregulated targets was enriched with genes that regulate cell adhesion 
and endothelium homeostasis, including fatty acid binding protein 4 (FABP4) 205, 
lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) 206 and apelin 
(APLN) 207 (Table 5). Strikingly, ERG and FLI1 knockdown induced remarkable 
overexpression of pro-inflammatory (CXCL10, HAS2, IL1A, CCL5, CXCL11, 
VCAM1) and interferon-responsive genes (GBP4, IFIT2, OASL, IRF6) (Table 4). 
Importantly, the quantitative PCR verification of C-X-C motif chemokine 10 
(CXCL10) and hyaluronan synthase 2 (HAS2), the targets found in the array, 
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showed a synergistic effect of ERG and FLI1 loss in inducing their gene 
expression (~2000 fold change for CXCL10 and ~50 fold change for HAS2) 
(Figure 12). We also verified the efficiency of the silencing of ERG and FLI1 by 
qPCR which was between 70-50% (Figure 12). 
In addition to the genes shown in Table 5, we measured the expression of 
other interferon pathway genes including interferon-induced guanylate-binding 
protein 1 (GBP1) (~15 fold change in a double siRNA treatment), interferon beta 
(IFNB1) (~130 fold change), interferon-induced protein 44-Like (IFI44L) (~12 fold 
change) and interferon regulatory factor 1, 7, and 9 (IRF1, 7, and 9) (2-5 fold 
change) as well as pro-inflammatory genes interleukin 8 (IL8) (~40 fold change) 
and chemokine (C-X3-C motif) ligand 1 (CX3CL1) (~30 fold change) (Figure 12). 
The response of those genes to ERG and FLI1 silencing showed similar 
synergistic effect in gene upregulation upon depletion of the two factors. In 
summary, simultaneous knockdown of ERG and FLI1 in HPAECs leads to 
upregulation of pro-inflammatory and interferon pathway-related genes in 
magnitudes exceeding that from knockdown of ERG or FLI1 alone.  
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Table 4 Top 20 genes upregulated in HPAEC following simultaneous ERG and 
FLI1 knockdown 
 
  
Gene Symbol Gene Name Fold change 
CXCL10 chemokine (C-X-C motif) ligand 10 116.73 
TNFSF13B tumor necrosis factor (ligand) superfamily, member 13b / BAFF 28.37 
HAS2 hyaluronan synthase 2 24.49 
IL1A interleukin 1, alpha 19.72 
CCL5 chemokine (C-C motif) ligand 5 17.97 
IDO1 indoleamine 2,3-dioxygenase 1 17.90 
GBP4 guanylate binding protein 4 17.38 
IFIT2 interferon-induced protein with tetratricopeptide repeats 2 14.59 
OASL 2'-5'-oligoadenylate synthetase-like 12.78 
HERC5 HECT and RLD domain containing E3 ubiquitin protein ligase 5 12.18 
CXCL11 chemokine (C-X-C motif) ligand 11 11.95 
VCAM1 vascular cell adhesion molecule 1 11.82 
RSAD2 radical S-adenosyl methionine domain containing 2 11.31 
LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein 11.15 
SECTM1 secreted and transmembrane 1 11.04 
RTP4 receptor (chemosensory) transporter protein 4 10.62 
IRF6 interferon regulatory factor 6 9.83 
PTGS2 
prostaglandin-endoperoxide synthase 
2 (prostaglandin G/H synthase and 
cyclooxygenase) 
9.69 
SEMA3C 
sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3C 
8.91 
TNFAIP3 tumor necrosis factor, alpha-induced protein 3 8.84 
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Table 5 Top 20 genes downregulated in HPAEC following ERG and FLI1 
knockdown. 
Gene Symbol Gene Name Fold Change 
FABP4 fatty acid binding protein 4, adipocyte -42.42 
LYVE1 lymphatic vessel endothelial 
hyaluronan receptor 1 
-18.04 
RGS7BP regulator of G-protein signaling 7 
binding protein 
-15.94 
DLL4 delta-like 4 (Drosophila) -12.06 
CHST1 carbohydrate (keratan sulfate Gal-6) 
sulfotransferase 1 
-11.52 
KIT v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene homolog 
-11.09 
TSPAN18 tetraspanin 18 -10.47 
ACE angiotensin I converting enzyme 
(peptidyl-dipeptidase A) 1 
-9.65 
C15orf54 chromosome 15 open reading frame 
54 
-9.62 
RASSF2 Ras association (RalGDS/AF-6) 
domain family member 2 
-9.02 
APLN apelin -8.80 
CXorf36 chromosome X open reading frame 36 -8.48 
PLEKHG1 pleckstrin homology domain 
containing, family G (with RhoGef 
domain) member 1 
-8.37 
CYTL1 cytokine-like 1 -8.37 
GDPD5 glycerophosphodiester 
phosphodiesterase domain containing 
5 
-8.14 
PLXNA4 plexin A4 -7.85 
CPNE5 copine V -7.28 
GPR116 G protein-coupled receptor 116 -7.25 
TRAC T cell receptor alpha constant -7.07 
ADAMTS18 ADAM metallopeptidase with 
thrombospondin type 1 motif, 18 
-6.88 
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Figure 12 Simultaneous loss of ERG and FLI1 in HPAEC induces the expression 
of inflammatory and interferon genes. Human pulmonary artery endothelial cells 
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(HPAECs) were subjected to siRNA-mediated silencing of FLI1 and/or ERG for 
48 h. Scrambled siRNA  (siSCR) was used as a control. Relative mRNA 
expression was determined by quantitative RT-PCR. n=3 independent 
experiments. Data shown as mean ±SD. One way ANOVA followed by Tukey’s 
multiple comparison were used for statistical analysis. *P<0.05, **P<0.01, 
***P<0.001  
 
 
Poly(I:C) and IFNβ1 treatments downregulate expression of ERG but not FLI1 
The interferon pathway plays an essential role in the innate immunity 
response to various pathogens and its activation is mediated via interferon 
receptors and Toll-like receptors (TLR). In our study we observed activation of 
interferon beta, which is specifically stimulated by TLR3. To test if there is a 
potential feedback mechanism between interferon beta pathway and ERG or 
FLI1, we treated HPAECs with the TLR3 agonist Poly(I:C) and the interferon 
receptor ligand IFNβ1. Treatment with 2.5 µg/ml Poly(I:C) downregulated ERG 
gene and protein expression over the course of time ranging from 1 h to 48 h, but 
had no effect on FLI1 (Figure 13 A, C). IFNβ1 (1000 U/ml) treatment 
downregulated ERG protein levels, but surprisingly did not significantly alter ERG 
gene expression (Figure 13 B, C). Similar to Poly(I:C), INFβ1 had no effect on 
FLI1 protein or gene expression (Figure 13 B, C).  
We next sought to verify whether the observed Poly(I:C) and INFβ1 
suppression of ERG protein is dependent on TLR3 and interferon receptor 
signaling by treating cells with 50 µM of a TLR3/complex inhibitor (TLR3i) or 0.1 
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µg/ml of a type I interferon-binding protein (B18R) before and during a 24-h 
Poly(I:C) or INFβ1 stimulation. Inhibition of TLR3 resulted in partial suppression 
of Poly(I:C)-mediated ERG depletion, whereas inhibition of interferon type I 
(B18R treatment) lead to a dose-dependent full suppression of Poly(I:C)-
mediated ERG depletion (Figure 13 D). B18R also blocked IFNβ1-mediated ERG 
downregulation, demonstrating that B18R is a potent inhibitor of type I interferon 
(Figure 13 D).  
 To our knowledge, direct regulation of INFB1 gene by ERG has not been 
previously demonstrated. We therefore performed chromatin immunoprecipitation 
with ERG specific antibody followed by quantitative PCR including the -129 to -
138 fragment of INFB1 promoter, which contains two putative ETS binding 
motifs. We show not only that ERG bound to IFNB1 promoter region, but also 
that this binding is significantly abolished by 6 h of Poly(I:C) treatment (p<0.01) 
(Figure 13 E). These results suggest that ERG serves as a transcriptional 
repressor of IFNB1 and that activation of TLR3 signaling leads to de-repression 
of IFNB1 by downregulating ERG. 
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Figure 13 Poly(I:C) and IFNβ1 treatment downregulate ERG but not FLI1. 
HPAEC were treated with 2.5 µg/ml Poly(I:C) (TLR3) agonist or and IFNβ1 for 
indicated periods of time. (A,B) Relative mRNA expression was determined by 
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quantitative RT-PCR (C) Representative western blot of HPAECs lysates treated 
with 2.5 µg/ml Poly(I:C) or 1000 U/ml IFNβ1 showing levels of FLI1 and ERG. 
n=3 independent experiments. (D) HPEACs were pre-treated with a 
TLR3/complex inhibitor (TLR3i, 50 µM) or interferon inhibitor B18R (0.1 and 0.2 
µg/ml) for 1 h and then incubated with Poly(I:C) or IFNβ1 for 24 h. (E) Chromatin 
immunoprecipitation using ERG antibody followed by quantitative RT-PCR with 
primers targeting IFNβ1 promoter region was performed on HPAECs treated for 
6 h with 2.5 µg/ml Poly(I:C). Data presented as a percent of input DNA recovery. 
n=3 independent experiments. All data shown as mean ±SD. One way ANOVA 
followed by Tukey’s multiple comparison were used for statistical analysis. 
*P<0.05, **P<0.01, ***P<0.001  
 
 
Overexpression of FLI1 and ERG attenuates Poly(I:C)-mediated interferon gene 
induction 
To demonstrate that ERG and FLI1 serve as transcriptional repressors of 
interferon genes in HPAECs, we overexpressed ERG and/or FLI1, followed by a 
3-h Poly(I:C) treatment. Adenoviral overexpression of ERG or FLI1, or ERG and 
FLI1 together, significantly reduced Poly(I:C)-induced IFNB1 overexpression 
(p<0.001) (Figure 14).Adenoviral overexpression of ERG and FLI1 together also 
reduced Poly(I:C)-induced GBP1 overexpression (p<0.05) (Figure 14). 
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Figure 14 Adenoviral overexpression of ERG and FLI1 reduces Poly(I:C)-
mediated interferon gene response. HPAEC were treated with control (ctrl), FLI1 
(F) or/and ERG (E) overexpressing adenovirus (Ad). After 24 h, a 2.5 µg/ml 
Poly(I:C) was added for 3 h. Relative mRNA levels of IFNB1 and GBP1 were 
measured by quantitative PCR. n=3 independent experiments. All data shown as 
mean±SD. One way ANOVA followed by Dunnett’s multiple comparison were 
used for statistical analysis. *P<0.05, **P<0.01, ***P<0.001. *P versus Ad-ctrl 
with no Poly(I:C); †P versus Ad-ctrl with Poly(I:C) 
 
 
Mice heterozygous for Erg and Fli1 have elevated inflammation in lungs 
To confirm important, synergistic role of ERG and FLI1 loss in vivo, we 
generated double heterozygous mice (Erg+/-Fli1+/-). As shown in Figure 15 A, 
adult mice (4 weeks old) were not present in Mendelian distribution, with Erg+/- 
being a skewing factor. 8-week old Erg+/-Fli1+/- mice, but not single 
heterozygotes, were also significantly smaller than wild type mice (p<0.05) 
(Figure 15 B), often exhibiting poor body condition (not shown). Erg+/-Fli1+/- 
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mouse lungs, as measured with quantitative PCR, had significantly elevated pro-
inflammatory and interferon-related gene expression (Figure 15 C). 
Immunostaining with the leukocyte marker CD45 and macrophage marker MAC3 
revealed increased interstitial immune cell infiltrate in double heterozygotes as 
compared with wild type littermates (Figure 15 D). Due to the abnormally small 
litters and difficulties in breeding, flow cytometry analysis or inflammatory 
challenge of animals was not feasible. In conclusion, simultaneous partial 
depletion of Erg and Fli1 in mice resulted in decreased survival and increased 
inflammtion in lungs. 
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Figure 15 Mice heterozygous for both Erg and Fli1 have elevated inflammation in 
lungs (A) Distribution of genotypes of adult (4 weeks old) mice as a result of 
breeding Erg+/- with Fli1+/- mice. ‘Expected’, calculated from Mendelian 
distribution, ‘observed’, number of pups that survived to adulthood. (B) Body 
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weight of 6-8 weeks old mice. (C) Gene expression of pro-inflammatory genes in 
whole lung of 6-8 weeks old mice as measured by quantitative RT-PCR. (D) 
Paraffin embedded lung sections were immunostained with CD45 and MAC3 
antibodies to visualize total leukocytes and macrophages, respectively. One way 
ANOVA followed by Tukey’s multiple comparison were used for statistical 
analysis. *P<0.05, **P<0.01, ***P<0.001.  
 
Discussion 
FLI1 is downregulated in the skin endothelium of SSc patients, but it was 
not known whether FLI1 is similarly downregulated in the endothelium of 
diseased pulmonary vasculature. We found low levels of FLI1 in the pulmonary 
endothelium in lung specimens from healthy subjects (data not shown) and a low 
degree of FLI1 downregulation in SSc-PAH and iPAH (data not shown). 
Interestingly, we found high expression of ERG, the closest homolog of FLI1, in 
the endothelium of healthy lungs in human and mouse.  
We also show, for the first time, that diseased lung endothelium in PAH, 
as well as in chronically hypoxic mice, xhibit loss of ERG. This result is in 
accordance with previous observations of endothelial ERG downregulation in 
human coronary disease and animal models treated with TNFα 203. It illustrates a 
universal mechanism of ERG suppression in injured vasculature. In our 
experiments, the perivascular ERG staining observed in examined mouse lung 
samples is likely due to non-specific staining, because primary nuclear 
localization of ERG is consistent with previously described ERG protein 
expression pattern in adult mammalian tissues 193.  
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In HPAECs, loss of ERG and FLI1 following siRNA-mediated gene knock-
down led to upregulation of a number of cytokines and interferon pathway genes, 
suggesting that FLI1 and ERG loss de-represses pro-inflammatory genes. 
Strikingly, double ERG and FLI1 knock-down, as compared to single knock-
downs, caused target gene upregulation in multiplicative degrees. This suggests 
that FLI1 and ERG synergistically regulate some transcriptional regulators of 
those pro-inflammatory genes. The interaction of FLI1 and ERG proteins has 
previously been demonstrated 208 and could potentially explain the co-operative 
transcriptional action of these two factors.  Further studies identifying the 
mediators involved in this process are of great importance to understanding the 
regulatory mechanism of endothelium homeostasis. 
It was previously demonstrated that the interaction of FLI1 and TGFβ 
signaling involves a feedback mechanism, where FLI1 represses TGFβ target 
genes and TGFβ downregulates activity of FLI1 80,82. By analogy, we sought for 
similar mechanism in FLI1 and ERG-mediated regulation of interferon type I. 
Overabundance of interferon type I signaling has been demonstrated in SSc-
PAH and is thought to have an important pathological role in disease 
development and progression 12,209. The source of the stimulatory signal is not 
known, but it has been speculated that viral infections and double stranded RNA 
(dsRNA) might be contributing to TLR-mediated activation of the innate immunity 
response. Our results clearly show that activation of interferon signaling through 
TLR3 significantly reduced ERG, but not FLI1 expression at both mRNA and 
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protein levels. In addition, we show that the IFNB1 gene is directly regulated by 
ERG binding to the IFNB1 promoter region and that interaction is lost upon TLR3 
activation, which corresponds with the decrease of ERG protein level in the same 
experimental conditions. Whichever event is first in initiation of the vascular 
disease is still not clear and needs to be further investigated.  
Lastly, we confirmed the importance of the ERG and FLI1 synergistic anti-
inflammatory effects in vivo by generating double heterozygous mouse Erg+/-
Fli1+/-. Heterozygosity for Erg seemed to be a factor decreasing mouse health 
and survival, because distribution of Erg+/- and Erg+/-Fli1+/- adult mice was non-
Mendelian and those mice had significantly reduced body mass. Erg+/- mice, 
however, did not have significantly elevated lung inflammation, which might be 
because that health issues in those animals were related to earlier 
developmental problems 210. Lungs of Erg+/-Fli1+/- mice had increased baseline 
gene expression of cytokines and interferon genes, as well as increased immune 
cell infiltration. As mentioned previously, breeding difficulties and small litters 
made it unfeasible to proceed with more elaborate experiments. 
In conclusion, endothelial ERG and FLI1 play essential roles in regulating 
vascular homeostasis including suppression of pro-inflammatory genes. 
Alterations of those factors might be therefore important contributors to the 
mechanism of vasculopathy in PAH and SSc.
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CHAPTER 5- DIMETHYL FUMARATE (DMF) PREVENTS AND REVERSES 
PULMONARY HYPERTENSION IN A MOUSE MODEL BY REDUCING 
INFLAMMATION, OXIDATIVE STRESS AND ENDOTHELIAL DYSFUNCTION 
 
Current therapies for PAH are limited and aim to reduce vasoconstriction 
and promote vasodilatation, but lack the ability to target the underlying 
mechanism of the disease. Given the complexity of SSc-PAH pathology, 
including pre-existing chronic inflammation and vasculopathy, we seek a drug 
capable of targeting multiple pathological pathways. 
Dimethyl fumarate (DMF) is a fumarate ester that is thought to work via 
induction of the anti-oxidative Nuclear factor (erythroid-derived 2)-like 2 (NRF2) 
pathway and inhibition of pro-inflammatory NFκB signaling. DMF has been 
shown to exert anti-oxidative, anti-inflammatory and anti-angiogenic properties in 
endothelial cells, anti-proliferative in smooth muscle cells, and anti-fibrotic in a 
kidney fibrosis mouse model. We therefore hypothesized that development and 
progression of PAH would be inhibited by DMF by targeting multiple pathological 
mechanisms of pulmonary vascular remodeling and dysfunction. We tested DMF 
in vivo in chronically hypoxic mice, as well as in vitro in ECs and SMCs. 
 
 
 
 
  
79 
Introduction 
Hypoxic mouse model of PAH 
There are only a few small animal models of PAH and none fully 
reproduces pathophysiological features 204,211. Chronic hypoxia triggers 
pulmonary vascular changes and therefore is commonly used in mice as a model 
of the disease 212,213. Hypoxic conditions induce vasoconstriction, SMC 
proliferation, and endothelial dysfunction. These changes are mediated through 
hypoxia-induced transcription factor 1 (HIF1) that regulates processes such as 
angiogenesis, proliferation, redox signaling, and cellular energetics 214. Hypoxia 
has also been shown to activate NFκB signaling, which is an important pro-
inflammatory pathway in PAH 215. 
 
Dimethyl fumarate 
Dimethyl fumarate (DMF) is a fumarate ester (Figure 16) that induces 
activation of the NRF2 pathway. DMF was historically used in Europe as an anti-
psoriasis topical medication and recently has been approved by the FDA as a 
multiple sclerosis treatment under the name Tecfidera. Overall, its safety record 
in multiple sclerosis and psoriasis has been encouraging. DMF has been shown 
to exert cytoprotective effects in neurons, anti-inflammatory and anti-angiogenic 
effects in ECs, anti-proliferative in SMCs, and anti-fibrotic in a mouse kidney 
fibrosis model 216-220. 
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Figure 16 Chemical structure of dimethyl fumarate (DMF). 
 
Known mechanisms of DMF action 
 
Activator of NRF2 pathway 
Vascular redox balance is largely mediated by the nuclear factor erythroid 
2 (NFE2)-related factor 2 (NRF2)-pathway. NRF2 regulates the expression of 
three groups of antioxidant response element (ARE)-dependent genes: 1) Drug 
metabolizing enzymes/transporters ((NAD(P)H: quinone oxidoreductase 
(NQO1)), 2) Antioxidant enzymes/proteins (Superoxide dismutase 3, Glutathione 
reductase, Thioredoxin, Heme oxygenase (HO-1)), and 3) oxidant signaling 
proteins (p62 protein, Parkinson disease 7 PARK7 (DJ-1), Protein tyrosine 
phosphatase) 221. As illustrated in Figure 17, in the absence of ROS or anti-
oxidants NRF2 activity is suppressed through Kelch-like erythroid cell-derived 
protein with CNC homology-associated protein 1 (KEAP1)-mediated 
ubiquitination and subsequent proteasomal degradation. Redox imbalance 
sensing and NRF-2 activation are assured by oxidation-sensitive thiols on 
DMF 
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cysteine residues located both on KEAP1 and NRF2. In addition to ROS, 
cysteine residues can also be modified by a variety of exogenous antioxidants, 
including phytochemicals and derivatives (curcumin,sulforaphane), therapeutics 
(oltipraz, auranofin), environmental agents (paraquat, arsenic), nitro-fatty acids, 
and 4- hydroxynonenal (4-HNE).  Modification of cysteine residues leads to 
dissociation of the NRF2-KEAP1 complex, stabilization of the NRF2 protein and 
its translocation to the nucleus, where it can serve as transcriptional activator. 
Posttranslational modifications have additional effects on the nuclear 
translocation/export, transcriptional activation, and stabilization of NRF2 222. They 
include phosphorylation /dephosphorylation (phosphorylation of serine (S) and 
threonine (T) residues by kinases such as PI3K, PKC, JNK, ERK and p38), and 
acetylation/deacetylation via the CREB-binding protein and sirtuin 1.  
Importantly, the oxidative stress response is coupled in an ill-defined 
manner to NFκB signaling with activation leading to an anti-inflammatory 
response. This effect is best illustrated by the excessive inflammatory response 
to injury seen in the Nrf2-/- mice, including increased NFκB activation, TNFα, IL-
1, IL-6 and ICAM expression 223. 
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Figure 17 Schematic of the regulation and the mechanism of NRF2 pathway. 
NRF2 in absence of stimuli such as ROS or anti-oxidants (sulphoraphane, 
curcumin, DMF) is ubiquitinated (Ub) by KEAP1 and send for proteasomal 
degradation. Upon stimulation, the KEAP1-NRF2 complex dissociates as a result 
of cysteine group (SH) being oxidized (SR). NRF2 can additionally be stabilized 
by phosphorylation of serine (S) and threonine (T) residues by variety of kinases 
(PI3K, PKC, ERK, p38). Stable NRF2 translocates to the nucleus, where it binds 
to antioxidant response element (ARE) and promotes expression of verity of anti-
oxidative and detoxifying enzymes (NQO1, HO-1, GPX, PRX).  
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Inhibitor of NFκB 
DMF is a well-known anti-inflammatory agent and has been successfully 
used to treat the inflammatory disease psoriasis 224. DMF reduces NFκB -
mediated expression of cytokines, adhesion molecules and other pro-
inflammatory mediators 225-227. Only recently has it been shown that NFκB 
inhibition by DMF is not dependent on the NRF2 pathway 228, and DMF directly 
inhibits NFκB signaling through the covalent modification of p65 (alkylation of a 
cysteine residue essential for p65 subunit function) 229. 
 
Agonist of a niacin receptor HCAR2 
Recent investigation into the mechanism DMF have shown that DMF is an 
agonist of Hydroxycarboxylic acid receptor 2 (HCAR2), a class of Gi receptors 
also known as GPR109A 230,231. HCAR2 is widely expressed on variety of 
immune cells including neutrophils, however it is not expressed in vascular cells 
(ECs, SMCs and fibroblasts). Interestingly, niacin, another ligand of HCAR2 with 
similar mechanisms of action as DMF, has been shown to have beneficial effects 
on vasculature and potentially inhibit lung fibrosis 232,233.  
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Results 
DMF ameliorates pathological hemodynamics in chronically hypoxic mice 
To assess the efficacy of DMF as a treatment for PAH we employed the 
chronic hypoxia mouse model. In the initial experiment, mice were challenged 
with hypoxia (10% O2) or normoxia for 21 days (Figure 18 Preventive). 
Experimental hypoxic and normoxic mice received daily i.p. injections of DMF (90 
mg/kg), while control hypoxic and normoxic mice were injected with vehicle. 
Direct measurement of right ventricular systolic pressure (RVSP) via closed 
chest catheterization through the right jugular vein showed increased RVSP (35 
mmHg) in hypoxic mice, which was significantly (p<0.001) lower in animals 
treated with DMF (27 mmHg) (Figure 18 B). Doppler echocardiographic imaging 
of the pulmonary artery blood flow is an accurate, fast and non-invasive method 
of assessing the changes in PAP. Shortened pulmonary acceleration time (PAT) 
and decreased PAT/ET(ejection time) correlate with increased RVSP 148. The 
echocardiographic measurement confirmed the catheterization results. The blood 
PA blood flow in hypoxic group had significantly (p<0.001) lower PAT/ET as 
compared to normoxic mice and DMF treatment normalized PAT/ET (Figure 18 
C). In addition, measurement of the weight of the right ventricle divided by the 
weight of the left ventricle and septum, suggestive of RV hypertrophy, revealed 
that DMF treatment prevented right ventricular enlargement (H vs. H+D, 
p<0.001) (Figure 18 D). Thus, this initial experiment demonstrated that DMF is 
capable of preventing increased RVSP and RV hypertrophy in hypoxic mice. To 
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test whether DMF treatment could reverse pre-existing pathological changes, the 
hypoxia challenge was extended to 42 days, and DMF or vehicle was 
administered daily starting from day 21 (Figure 18 A, Therapeutic). Mice exposed 
to prolonged hypoxia showed further changes in PAT/ET (indicative of RVSP) 
and RV hypertrophy compared to the mice challenged for 21 days (Figure 18 C, 
D). Despite the presence of these changes, DMF treatment still normalized 
PAT/ET (p<0.001) and RV hypertrophy (p<0.001) to an extent comparable to 
preventive treatment. These results indicate that DMF effectively prevents and 
reverses hypoxia induced elevated RVSP and RV hypertrophy. 
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Figure 18 DMF abrogates hypoxia-induced increase in RV blood pressure and 
RV hypertrophy in vivo. (A) Experimental design for preventive and therapeutic 
DMF treatment modes. In the preventive mode mice were kept in normoxia (N) or 
hypoxia (H) (10%O2) for 21days and injected daily with 90mg/kg DMF(D) or 
vehicle. In the therapeutic mode mice were kept in hypoxia for a total of 42 days 
with daily DMF injections starting at day 21. (B) The RV systolic blood pressure 
was measured by catheterization for the mice in the preventive experiment. n=4 
mice for normoxia, n=6 mice for hypoxia and n=6 for hypoxia+DMF (C) 
Pulmonary acceleration time (PAT) and PAT as a fraction of ejection time 
(PAT/ET) were measured in normoxic and hypoxic mice ± DMF treatment in 
preventive and therapeutic modes. n=4 mice for normoxia+DMF, n=6 mice for 
other groups. (D) The weight ratios of the right ventricle to the left ventricle plus 
septum (S)  (RV/(LV+ S)) were calculated as indices of RV hypertrophy. n=6 
mice per group. *P<0.05, **P<0.01, ***P<0.001. 
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DMF mitigates oxidative stress damage and inflammation in lungs  
We next assessed the ability of DMF to alleviate oxidative stress in 
hypoxic lungs. The extent of damage caused by oxidative stress was visualized 
by nitrotyrosine immunofluorescent staining and was shown to be prominently 
upregulated by hypoxia (Figure 19 A). DMF markedly reduced nitrotyrosine 
formation in the preventive treatment group and was partially effective in the 
therapeutic group. Likewise, the hypoxia-induced elevated expression of Nox4 
NADPH oxidase, a source of hydrogen peroxide in the pulmonary vasculature, 
was normalized by the preventive DMF treatment, but only partially by the 
therapeutic treatment (Figure 19 B). Interestingly, the NRF2-responsive anti-
oxidative HO-1 (heme oxygenase) gene was significantly elevated by DMF in 
only hypoxic mice and not in normoxic mice (N vs. H+D p<0.001 for preventive, 
p<0.01 for therapeutic) (Figure 19 B). 
One of the pathological consequences of excessive production of oxidants 
is increased inflammation 234. To determine the effect of DMF on lung 
inflammation, the expression of cytokines interleukin 6 (Il-6), oncostatin M (Osm), 
C-C motif chemokine ligand 2 (Ccl2) and the adhesion molecule Icam-1 was 
assessed using qPCR, while tissue infiltration by leukocytes and macrophages 
was quantified by immunostaining for cell type specific markers: CD45 and 
MAC3, respectively. DMF treatment effectively inhibited hypoxia-induced 
inflammation in all treatment groups (Figure 19 C-E). Together, these results 
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indicate that DMF reduces pulmonary oxidative stress damage and inflammation 
in vivo. 
 
 
Figure 19 Attenuation of hypoxia-induced pulmonary oxidative stress damage 
and inflammation by DMF treatment. (A) Representative pictures of 
immunofluorescent staining of mouse lungs using anti-vWF antibody and anti-
nitrotyrosine antibody as a marker of oxidative damage. Normoxia (N), Hypoxia 
(H), DMF treatment (D). (B,C) qPCR quantification of relative mRNA levels in a 
whole lung. (B) Expression of Nrf2 responsive anti-oxidative gene Ho-1 and 
NADPH oxidase Nox4.  (C) Expression of Il-6 family cytokines: Il-6 and Osm, 
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Ccl2, and Icam1. n=6 mice per group. (D,E) Frozen lung sections from the 
preventive mode experiment were immunostained using anti-MAC3 (D) antibody 
as a general macrophage marker and anti-CD45 (E) antibody as a general 
leukocyte marker. Positive cells were counted from 5 fields of view per mouse. 
n=4 mice per group, data shown as mean ± SD. *P<0.05, **P<0.01, ***P<0.001. 
 
 
DMF inhibits STAT3-, NFκB- and cJUN-mediated activation of endothelial cells in 
vitro 
Injured endothelial cells are known to produce cytokines and chemokines 
that escalate the inflammatory activation of the vasculature 235. The effect of DMF 
on activation of endothelial cells was investigated using human pulmonary artery 
endothelial cells (HPAECs) exposed to hypoxia (2.5% O2) in culture. 
Experiments to determine an optimal concentration of DMF found maximum HO-
1 expression following treatment with 10 µM DMF (data not shown). DMF (10 
µM) significantly reduced basal mRNA levels of OSM and ICAM1 and prevented 
hypoxia-induced upregulation of NOX4 (p<0.05), IL-6 (p<0.05), OSM (p<0.05) 
and ICAM1 (p<0.05) (Figure 20 B-C), as well as the pro-fibrotic and pro-
proliferative genes known to be involved in PAH pathology 236,237: ET-1 (p<0.01), 
CTGF (p<0.05), PDGFB (p<0.01) and TGFβ (p<0.05) (Figure 21). We next 
examined the effects of DMF on the pro-inflammatory cell signaling pathways 
relevant to PAH. Hypoxia induced phosphorylation of STAT3 (activating 
phosphorylation at residues S727 and Y705) and c-JUN, while DMF treatment 
abrogated the hypoxia-induced phosphorylation of both proteins (Figure 20 D). 
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Under hypoxic conditions, activation of NFκB was not consistently observed and, 
therefore, we examined lipopolysaccharide (LPS)-triggered NFκB activation in 
HPAECs. Based on previously published data in mouse splenocytes 228, we used 
a higher dose of DMF (30 µM), which significantly diminished (p<0.001) the 
activity of the NFκB luciferase reporter after LPS (10 ng/ml) stimulation (Figure 
20 E). We next determined whether the anti-oxidative NRF2 pathway was 
required for the anti-inflammatory effect of DMF. Consistent with the previous 
study 228, the knock down of NRF2 did not affect the ability of DMF to block the 
LPS-induced expression of pro-inflammatory genes in HPAECs (Figure 22). 
These observations show that DMF can prevent endothelial cell activation, 
possibly through DMF-mediated inhibition of major pro-inflammatory pathways: 
NFκB, STAT3 and cJun.  
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Figure 20 DMF inhibits pro-inflammatory gene expression in endothelial cells by 
suppressing NFκB, STAT3 and cJUN signaling. (A,B,C,E) HPAECs were 
incubated for up to 24h in (H) hypoxia (2.5% O2) or (N) normoxia (21% O2) with 1 
x 10-5 mol/l DMF (D) or DMSO. Relative gene expression was measured with 
qPCR: (A) HO-1, (B) Nox4, (C) pro-inflammatory genes: OSM, IL-6 and ICAM-1. 
n=4 independent experiments. (D) 10 µM DMF treatment reduced the 
phosphorylation of STAT3 and c-JUN in HPAECs exposed to hypoxia for 4h. 
Representative immunoblots and densitometry quantification are shown. n=3 
independent experiments. (E) NFkB activity luciferase reporter assay was 
performed in HPAECs in presence of 10ng/ml LPS (L) and/or 30µM DMF (D), 
control cells treated with DMSO (C). n=3 independent experiments. Data shown 
as mean ± SD. *P<0.05, **P<0.01, ***P<0.001.  
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Figure 21 . DMF inhibits hypoxia-induced expression of pro-fibrotic and 
proliferative genes in HPAECs.Gene expression in hypoxic (H) or normoxic (N) 
HPAECs treated with DMF (D) as measured by qPCR. ). n=3 independent 
experiments. Data shown as mean ± SD. *P<0.05, **P<0.01, ***P<0.001 
 
 
 
Figure 22 NRF2 is not required for the anti-inflammatory action of DMF in LPS-
stimulated HPAECs. Gene expression of HPAECs treated with siRNA against 
NRF2, followed by LPS and DMF treatments. Relative expression measured by 
qPCR. ). n=3 independent experiments. Data shown as mean ± SD. *P<0.05, 
**P<0.01, ***P<0.001 
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Pulmonary vascular muscularization in vivo and hypoxia-induced changes in 
human pulmonary arterial vascular smooth muscle cells are reduced by DMF 
To assess the effects of DMF on vascular remodeling, we performed 
immunostaining with antibodies to vWF, a vascular endothelium marker, and 
αSMA, a smooth muscle cell marker (Figure 23 A). Vascular muscularization was 
quantified and presented as the percent of peripheral pulmonary arterioles that 
were fully, partially or non-muscularized. The numbers of partially and fully 
muscularized vessels were elevated to a similar extent in mice challenged with 
hypoxia for 21 and 42 days. DMF significantly ameliorated vascular 
muscularization in both treatment groups (fully muscularized vessels H vs. H+D 
p<0.001 for preventive and p<0.01 for therapeutic treatment group) (Figure 23 
B).  
In our translational studies of direct DMF effect on vascular smooth 
muscle cells, we cultured pulmonary arterial vascular smooth muscle cells from 
the distal vasculature of lungs obtained from two patients with end-stage 
pulmonary hypertension at the time of organ transplantation and one healthy 
control. Cells were treated with normoxia or hypoxia (1% O2) for 24 h ± DMF (50 
µM) and the PAH-related 238 gene transcript levels determined via qPCR. We 
found that DMF treatment reduced angiostatic thrombospondin-1 (TSP1) 
transcript levels in healthy control (HC) and pulmonary hypertension (PH) 
HPASMCs under normoxic (p<0.001) and hypoxic (p<0.001) conditions (Figure 
23 C). Acute hypoxia lowered TSP1 mRNA in HC and PH HPASMC (p<0.001). 
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We previously reported that TSP1 mRNA levels increased after hypoxia (1% O2, 
24h) in HPASMC cultured under sub-confluent and growth factor/serum-
restricted media conditions 239. In contrast, we now find that hypoxia suppresses 
TSP1 mRNA in sub-confluent HPASMC cultured in complete medium containing 
serum and growth factors. Restriction of growth factors and serum in cultured 
vascular smooth muscle cells is known to limit cell cycle progression 240. Our new 
data thus suggest that transcriptional regulation of TSP1 is cell cycle and growth 
factor linked in HPASMC.   
Notably, ET-1 transcript levels were increased in hypoxic PH HPASMC 
following hypoxia challenge (p<0.001) but not in HC cells, while DMF treatment 
resulted in decreased ET-1 mRNA levels in HC and PH HPASMC under both 
hypoxic and normoxic conditions (Figure 23 C). DMF treatment inhibited (COL)-
1α1 transcript levels under normoxic conditions in HC cells (p<0.001). Likewise, 
DMF treatment inhibited hypoxia-induced changes in (COL)-1α1 and -4α1 mRNA 
in HC HPASMC (p<0.001) but had no effect in PH HPASMC. In summary, DMF 
prevents and reverses hypoxia induced vascular muscularization in vivo and has 
a beneficial effect on cultured vascular smooth muscle cells isolated from PH 
patients. 
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Figure 23 DMF inhibits vascular muscularization in hypoxic mice and suppresses 
hypoxia-induced gene expression in human PASMCs. (A) Representative 
pictures of immunostaining of mouse lung sections with anti-vWF and anti-αSMA 
antibodies. (B) Intra-acinar vessels ranging from 20 to 70 µm in size were 
counted and categorized into non muscularized, partially muscularized, or fully 
muscularized. n=4 mice per group. (C) Smooth muscle cells were incubated in 
hypoxia (H) (1% O2) or normoxia (N) for 24 hours with 50 µM DMF or DMSO. 
Relative gene expression was measured with qPCR. n=1 for healthy control (HC) 
and n=2 for pulmonary hypertension (PH) cell lines, two independent 
experiments were performed. *P versus normoxia(N); †P  versus hypoxia(H).  
Data shown as mean ± SD. *P<0.05, **P<0.01, ***P<0.001.  
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Discussion 
The mortality rate of PAH is approximately 55-65% at three years with a 
poorer response to treatment and a worse prognosis for SSc-PAH patients (an 
unadjusted risk of death of 2.9 when compared to idiopathic PAH) 140,241. The 
complexity of PAH, including impaired redox homeostasis, abnormal vascular 
remodeling, adventitial fibrosis and immune cell activation suggests that 
simultaneous pharmacological modulation of multiple key pathways may be 
required for the effective treatment of PAH. Here we show that DMF has multiple 
modes of action that may ameliorate PAH. DMF not only prevented the 
development of increased PAP, right heart hypertrophy and pulmonary vascular 
muscularization, but also reversed pre-existing disease in a chronic hypoxia 
mouse model. DMF treatment efficiently reduced the contributions of pathogenic 
pathways in several cell types associated with PAH, including vascular and 
immune cells.  
The potent anti-inflammatory and anti-oxidative effects of DMF are of 
particular relevance inflammation and oxidationhave been increasingly 
recognized as being pivotal in PAH pathogenesis. For example, IL-6 is elevated 
in serum and lung tissues of patients with PAH and Il-6 overexpressing mice 
spontaneously develop PAH 134. Several studies have shown that increasing anti-
oxidative potential and inhibiting key pro-inflammatory pathways such as ΝFκΒ is 
sufficient to prevent vascular remodeling in experimental models of PAH 242-244. 
Our study demonstrates that DMF inhibits crucial pro-inflammatory pathways, 
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including ΝFκΒ, STAT3 and cJUN in pulmonary endothelial cells, which 
correlates with decreased lung tissue infiltration by macrophages and immune 
cells in vivo and reduced expression of IL-6 in hypoxic mice. Others have shown 
that DMF inhibits HIF1α expression and function 245, which might further explain 
the beneficial effects of DMF in PAH. 
One of the pathological characteristics of pulmonary vascular remodeling 
is muscularization of small arterioles. DMF prevented and reversed vascular 
muscularization,in hypoxic mice, which could be explained by DMF potential to 
inhibit production of pro-proliferative factors such as ET-1, CTGF, TGFβ and 
PDGF by ECs. It is well established that a crosstalk between ECs and SMCs via 
paracrine signaling promotes SMC proliferation and medial thickening in PAH 246. 
The ability of DMF to change the expression of key PAH-related genes was 
tested using freshly harvested pulmonary arterial smooth muscle cells (PAMSC) 
from patients with and without PH. Treatment with DMF altered mRNA levels of 
several genes including TSP1, ET-1 and collagen genes, all of which have been 
found to promote experimental PAH, and one of which is therapeutically targeted 
in clinical PAH (ET-1) 247. Our results were limited by the small number of human 
samples. Nonetheless, these data suggest that DMF can suppress key PAH-
associated genes in HPASMC from lungs of individuals with end-stage PH.   
In conclusion, this study demonstrates that DMF can ameliorate PAH in 
vivo and block multiple PAH-related pathological pathways in vitro, therefore 
strongly supporting the testing of DMF as a therapy for patients with PAH.
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CHAPTER 6 – DIMETHYL FUMARATE (DMF) PREVENTS LUNG AND SKIN 
FIBROSIS IN VIVO AND IN VITRO 
Despite significant therapeutic advancements, pulmonary complications in 
SSc are associated with high mortality, and there is currently no effective 
treatment. Prominent skin and organ fibrosis is a hallmark feature of SSc and is 
accompanied by fibroproliferative vasculopathy and immune dysfunction. 
Deregulated fibrotic process also plays a critical role in the pathogenesis of SSc-
related PAH. Recent research suggests that activated adventitial fibroblasts 
contribute to the structural changes in the pulmonary vasculature by promoting 
immune cell infiltration. To directly test the anti-fibrotic properties of DMF we 
utilized the mouse bleomycin-induced lung and skin fibrosis model, as well as 
patient-derived fibroblasts in vitro. 
 
 Introduction 
Bleomycin mouse model of skin and lung fibrosis 
Bleomycin is a chemotherapeutic agent and antibiotic used for the 
treatment of lymphoma, squamous cell carcinomas, germ cell tumors and 
malignant pleural effusion 248. In cancer treatment bleomycin acts by inducing 
single and double-strand DNA breaks in proliferating cancer cells and thereby 
interrupting the cell cycle 249. In a bleomycin animal fibrosis model, DNA damage-
induced oxidative stress triggers inflammation, which is a potent driver of pro-
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fibrotic process. The “switch” between inflammation and fibrosis appears to occur 
around day 9 after bleomycin administration in the mouse model 250. 
To induce the skin fibrosis with bleomycin, two methods has commonly 
been utilized, subcutaneous injections and osmotic pump 251. Intra-tracheal, 
subcutaneous, intraperitoneal (i.p.) and intravenous injections are used for 
induction of lung fibrosis 252-254. 
 
Results 
DMF prevents bleomycin-induced skin fibrosis in vivo 
Mice receiving bleomycin showed an increased thickness of the dermis 
with a markedly reduced adipose layer, as visualized by Gomori trichrome 
staining (Figure 24 A Bleo+VEH). In a majority of bleomycin treated mice (4/5 of 
mice), which were given daily DMF i.p. injections, skin thickness was reduced 
and the adipose layer was normalized (Figure 24 A  Bleo+DMF). In addition, 
bleomycin-treated mice showed increased numbers of αSMA positive cells, 
representing activated fibroblasts, which were localized predominantly in the 
hypodermis (Figure 24 B Bleo+VEH) and DMF markedly reduced the number of 
αSMA expressing cells (Figure 24 B Bleo+DMF). DMF treatment also reduced 
bleomycin-induced gene expression of Col1α1 (p<0.01), Ctgf (p<0.05), Et-1 
(p<0.05) and Il-6 (p<0.01) in skin (Figure 24 C).   
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Figure 24 DMF prevents bleomycin-induced skin fibrosis. (A,B,C) Stainings of 
skin section of bleomycin mouse model. (A) Gomori trichrome staining, (B) αSMA 
immunostaining. (C) quantitative PCR measurment of pro-fibrotic gene 
expression in a whole skin from bleomycin mice. *P<0.05, **P<0.01, ***P<0.001 
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DMF inhibits the pro-fibrotic gene expression induced by TGFβ in dermal 
fibroblasts  
To examine the effects of DMF on the fibrogenic process in SSc patient-
derived dermal fibroblasts we treated cells in culture with 2.5ng/ml TGFβ and 
with DMF ranging from 0-100 µM for 4 h. This preliminary experiment indicated 
that a dose of 50 µM DMF is sufficient to efficiently block TGFβ-
mediated rapid induction of pro-fibrotic genes including ET-1 and CTGF, as well 
as significantly induce NRF2-dependent gene expression of anti-
oxidative heme oxygenease 1 (HO-1) (Figure 25 a). We next verified the 
expression levels of genes in HC and SSc fibroblasts relevant to SSc fibrosis, 
such as CTGF, ET-1, collagen 1 (COL1A1) and IL-6 (Figure 25 b-e). The basal 
levels of CTGF, ET-1 and IL-6 were slightly and COL1A1 significantly elevated 
(~4 fold, p<0.01) in SSc fibroblasts as compared to HC fibroblasts. DMF was 
able to moderately reduce basal levels and markedly suppress TGFβ-
mediated upregulation of those genes at 6 h (SSc CTGF p<0.001, HC CTGF 
p<0.001, SSc ET-1 p<0.001, SSc IL-6 p<0.001, HC IL-6 p<0.01), 24 h (SSc 
CTGF p<0.001, HC CTGF p<0.001, SSc COL1A1 p<0.001, HC COL1A1 p<0.05, 
SSc ET-1 p<0.001, HC ET-1 p<0.05, SSc IL-6 p<0.001, HC IL-6 p<0.001) and 48 
h (SSc COL1A1 p<0.001, HC COL1A1 p<0.001) time points. Additionally, DMF 
significantly reduced CTGF protein expression and secreted Collagen I upon 
TGFβ treatment (Figure 25 b-e). 
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Figure 25 DMF inhibits the pro-fibrotic response of dermal fibroblasts to TGFβ. 
(A) SSc skin fibroblasts were treated with TGFβ and 0-100 uM DMF for a 
duration of 3h. (B-E) HC and SSc fibroblasts were treated with TGFβ and DMF 
for 6, 24 and 48 h. Relative gene expression was measured with quantitative 
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PCR and relative protein levels by Western blot. n=3 cell lines per group. Data 
shown as mean ± SD. *P versus control(C); †P versus TGFβ(T). *P<0.05, 
**P<0.01, ***P<0.001. 
 
 
DMF prevents bleomycin-induced lung fibrosis in vivo 
Bleomycin-treated mice injected with vehicle developed pulmonary fibrosis 
as visualized by trichrome staining of the lung sections (Figure 26 A, 
BLEO+VEH). In contrast, in three out of five mice treated with bleomycin plus 
DMF there were no detectable pathological changes in lung histology (Figure 26 
A, BLEO+DMF, lower panel), while the other two DMF-treated mice exhibited 
some residual subpleural fibrotic plaques (Figure 26 A, BLEO+DMF, upper 
panel). Consistent with the results of the histological analysis, DMF inhibited the 
expression of major pro-fibrotic genes that were upregulated by bleomycin 
treatment, including Col1α1 (p<0.05), Col5α1 (p<0.05), Ctgf (p=0.0656), Et-1 
(p=0.0506), and tissue inhibitor of metalloproteinase 1 (Timp1) (p<0.01) (Figure 
26 B). In addition, DMF also reduced the bleomycin-induced expression of the 
pro-inflammatory genes Ccl2 (p<0.01), Il-6 (p=0.0867), and Icam-1 (p<0.01) 
(Figure 26 B), which are known to be essential for the fibrotic processes in the 
bleomycin model. Taken together, DMF effectively prevented development of 
lung fibrosis in vivo. 
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Figure 26 DMF prevents development of pulmonary fibrosis in bleomycin mouse 
model. (A) Gomori trichrome staining of lung sections from bleomycin mouse 
model. (B) Quantitative PCR measurment of pro-fibrotic gene expression in a 
whole lung tissue. n=3-5 mice per group. P<0.05, **P<0.01, ***P<0.001 
  
B 
PBS BLEO+
VEH
BLEO+
DMF
0
1
2
3
4
5
fo
ld
 ch
an
ge
Ho-1
*
PBS BLEO+
VEH
BLEO+
DMF
0
2
4
6
8 Nox4
* **
PBS BLEO+
VEH
BLEO+
DMF
0
5
10
15
20 Il-6
0.2364 0.0867
PBS BLEO+
VEH
BLEO+
DMF
0
10
20
30
40
50 Icam1
* **
PBS BLEO+
VEH
BLEO+
DMF
0
2
4
6
8
10 Et-1
0.1525 0.0506
PBS BLEO
+VEH
BLEO
+DMF
0
5
10
15 Ccl2
** **
PBS BLEO
+VEH
BLEO
+DMF
0
2
4
6
8
10
fo
ld
 ch
an
ge
Col1 1
* *
PBS BLEO
+VEH
BLEO
+DMF
0
1
2
3
4
5 Ctgf
** 0.0656
PBS BLEO
+VEH
BLEO
+DMF
0
10
20
30 Timp1
* **
BL
EO
+D
M
F 
BL
EO
+D
M
F 
4x 20x 
"%
&
'()
*+
$
"%
&
'()
*+
$
"%
&
'()
*+
$
"%
&
'()
*+
$
BL
EO
+V
EH
 
PB
S 
!"
#$
"%
&
'$
"%
&
'()
*+
$
"%
&
'()
*+
$
,-$ ./-$ 0/-$./-$ 04x 20x A 
100μm 500μm 
PBS BLEO
+VEH
BLEO
+DMF
0
1
2
3
4 Col5 1
0.1328 *
  
105 
 
TGFβ-mediated activation of patient-derived lung fibroblasts is inhibited by DMF 
The anti-fibrotic properties of DMF were examined further in vitro using 
TGFβ-stimulated human lung fibroblasts. Lung fibroblasts obtained from SSc 
patients and healthy controls were stimulated with TGFβ for 24 h. As expected, 
TGFβ induced significant increase in expression of the pro-fibrotic genes, 
including COL1A1 (HC p<0.05, SSc p<0.01), COL1A2 (HC p<0.05, SSc p<0.05), 
CTGF (HC p<0.05, SSc p<0.01), PAI1 (HC p<0.01, SSc p<0.01), ET-1 (HC 
p<0.05, SSc p<0.001), and αSMA (HC p<0.05, SSc p<0.01), in both SSc and HC 
lung fibroblasts, with SSc fibroblasts exhibiting larger magnitude of response 
(Figure 27 A). DMF reduced basal mRNA expression levels of ET-1, αSMA, 
COL1A1, COL1A2 and significantly reduced basal protein levels of CTGF and 
collagen type I (Figure 27 A). The pro-fibrotic response to TGFβ in HC and SSc 
fibroblasts was significantly blocked by DMF in all the genes we examined 
(Figure 27). Surprisingly, the major TGFβ-responsive pro-fibrotic signaling 
pathway involving SMAD2/3 and SMAD1/5 phosphorylation was not significantly 
affected by DMF treatment (Figure 27 B). Thus, DMF inhibits pro-fibrotic effect of 
TGFβ without affecting the SMAD pathway. 
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Figure 27 TGFβ –induced lung fibroblast activation is inhibited by DMF. (A,B) 
Human primary lung fibroblasts from healthy controls (HC) and scleroderma 
patients (SSc) were treated for (A) 24h with 2.5ηg/ml TGFβ(T) and 90µM 
DMF(D), control cells (C) were treated with vehicle (DMSO), or (B) pre-treated for 
1h with DMF(D) and then exposed to TGFβ(T) for 30min. (A) Relative gene 
expression was measured with qPCR. CTGF and COLI proteins were measured 
by densitometry of immunoblots from the whole cell lysates. (B) Representative 
immunoblots and densitometry measurements of pSMAD2 and pSMAD1/5 
levels. n=3 cell lines per group. Data shown as mean ± SD. *P versus control(C); 
†P versus TGFβ(T). *P<0.05, **P<0.01, ***P<0.001. 
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NRF2 is not required for anti-fibrotic DMF properties in vitro 
Knock down of NRF2 in fibroblasts demonstrated that the inhibitory effect 
of DMF on the TGFβ-mediated pro-fibrotic response was independent of NRF2 
(Figure 28). In contrast NRF2 was required for DMF inhibition of TGFβ-induced 
expression of NOX4.  
 
 
 
Figure 28 NRF2 is not required for the anti-fibrotic action of DMF in lung 
fibroblasts treated with TGFβ. IMR90 lung fibroblasts were treated with NRF2 
targeting siRNA or scrambled siRNA (SCR) for 24 h and then treated with TGFβ 
(T) and DMF (D) for another 24 h. Control cells (C). Relative gene expression 
was measured with qPCR. n=3 independent experiments Data shown as mean ± 
SD. *P<0.05, **P<0.01, ***P<0.001. 
 
  
C C T T+D
0.0
0.2
0.4
0.6
0.8
1.0
fo
ld
 ch
an
ge
NRF2
SCR 
siRNA
NRF2 
siRNA
C C T T+D
0
10
20
30
40
50
60
SCR 
siRNA
NRF2 
siRNA
**
NOX4
C C T T+D
0
2
4
6
8
10
SCR 
siRNA
NRF2 
siRNA
** ***
αSMA
C C T T+D
0
10
20
30
40 ET1
SCR 
siRNA
NRF2 
siRNA
** **
C C T T+D
0
5
10
15
20
25
30 CTGF
SCR 
siRNA
NRF2 
siRNA
** **
C C T T+D
0
3
6
9
12
15
* *
SCR	
siRNA
NRF2	
siRNA
COL1α1
  
108 
DMF promotes βTRCP-dependent proteasomal degradation of Sp1, β-catenin 
and TAZ 
To elucidate further the anti-fibrotic mechanism of DMF, we examined 
other signaling pathways involved in the pathological fibrotic process. Because 
the Wnt/β-catenin pathway is implicated in pulmonary fibrosis 255, we examined 
the effect of DMF treatment on the protein levels of the Wnt signaling effector 
molecule, β-catenin (Figure 29). Consistent with previous reports 256, TGFβ 
upregulated the level of β-catenin protein and DMF significantly reduced both 
basal and TGFβ-induced levels of β-catenin in both healthy control and SSc 
fibroblasts (Figure 29 A). These findings were further corroborated in lung tissue 
sections from bleomycin-treated mice where increased numbers of active 
(unphosphorylated) β-catenin-positive cells in the fibrotic regions were 
normalized by DMF treatment (Figure 30). 
Degradation of β-catenin is coupled to degradation of the Hippo pathway 
effector, WW domain containing transcription regulator 1 (TAZ), which is also a 
major transactivator of the CTGF promoter 257. Like β-catenin, protein levels of 
TAZ were elevated in response to TGFβ  but reduced by DMF treatment (Figure 
29 A).  This observation suggested that DMF regulates the protein stability of 
both β-catenin and TAZ. To explore this possibility, we treated fibroblasts with the 
proteasomal inhibitor MG132 before addition of TGFβ and DMF. Indeed, 
inhibition of the 26S proteasome completely suppressed the ability of DMF to 
regulate protein levels of β-catenin and TAZ (Figure 29 B). Likewise, TGFβ 
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upregulation of β-catenin and TAZ no longer occurred. It is possible that DMF 
could upregulate 26S proteasome activity in a general fashion.  However, we 
found that protein levels of SMAD2/3, another known 26S proteasome target, 
were not affected by DMF treatment suggesting that the effects of DMF on 
proteasome activity are at least partially selective (Figure 29 B).  
Proteosomal degradation of β-catenin and TAZ is promoted by βTRCP, a 
component of the E3 ubiquitin ligase 258,259. siRNA suppression of βTRCP, 
mitigated DMF-mediated degradation of β-catenin and TAZ (Figure 29 C). 
Interestingly, in the absence of βTRCP, TGFβ-mediated stabilization of TAZ was 
not affected, while β-catenin was no longer responsive to TGFβ treatment. These 
data suggest that although these two transcription co-factors experience 
common βTRCP-mediated proteasomal degradation, additional pathways 
specific for each factor contribute to their regulation. In addition, we verified that 
DMF stimulates βTRCP-specific degradation by showing that SMAD2/3 remained 
unchanged in the βTRCP-silenced cells (Figure 29 C). 
Since DMF reduced the levels of proteins regulated by βTRCP, we 
postulated that expression of the βTRCP target protein Sp1 260,261, an essential 
regulator of collagen genes (49), would be impacted. DMF reduced the basal 
Sp1 protein levels (Figure 29 D) and similar to the results for TAZ and β-catenin, 
proteasome inhibition blocked the effects of DMF. The effects of DMF on Sp1 
levels were linked to βTRCP because knockdown of βTRCP eliminated the effect 
of DMF (Figure 29 B-C). To confirm the functional significance of Sp1 regulation 
  
110 
by DMF, we employed chromatin immunoprecipitation and luciferase activity 
promoter assays. These assays revealed that COL1α2 promoter activity, as well 
as binding of Sp1 to the COL1α2 promoter, are significantly reduced by DMF 
(Figure 29 E-F).  
In conclusion, the studies in human lung fibroblasts implicate βTRCP-
dependent, 26S proteasome-mediated degradation of Sp1, β-catenin and TAZ as 
a mechanism for the anti-fibrotic activity of DMF. 
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Figure 29 DMF promotes βTRCP-mediated degradation of Sp1, β-catenin and 
TAZ. (A,D) Lung fibroblasts from patients were treated for 24 h with TGFβ(T) and 
DMF(D) or vehicle (C). Representative immunoblots and densitometry 
measurements of β-catenin and TAZ. n=3 cell lines per group. (B) Lung 
fibroblasts (IMR90) were pre-treated with proteasome inhibitor MG132 for 1 h 
and then exposed to TGFβ with DMF or vehicle for 24h. (C) IMR90 were silenced 
with scrambled siRNA (SCRsiRNA) or βTRCP siRNA and then treated with TGFβ 
with or without DMF treatment for 24 h. Representative immunoblots are shown. 
(D) Representative immunoblots and densitometry measurements of Sp1. (E) 
Lung fibroblasts were transfected with COL1α2 promoter reporter and then 
treated for 24 h with DMF or vehicle. n= 3 independent experiments (F) 
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Chromatin immunoprecipitation using Sp1 antibody was performed after 24 h 
treatment with TGFβ and DMF or vehicle. The amount of recovered DNA was 
measured with qPCR.  n= 3 independent experiments.  Data shown as mean ± 
SD. *P versus control(C); †P  versus TGFβ(T). *P<0.05, **P<0.01, ***P<0.001. 
 
 
Figure 30 Lung fibrotic regions are enriched in active β-catenin positive cells. 
Staining of bleomycin mice lung sections with active (unphosphorylated) β-
catenin antibody and Gomori Trichrome. 
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DMF promotes matrix remodeling by inducing MMP1 expression in fibroblasts 
MMP1, secreted by fibroblasts and other cells, is an interstitial 
collagenase that promotes collagen degradation. It is hypothesized that reduced 
MMP1 levels may contribute to excessive collagen deposition. Indeed, reduced 
MMP-1 is seen in patients with SSc and TGFβ is known to inhibit MMP1 
expression 262 263. Our group has also demonstrated that MMP-1 expression is 
positively regulated via ERK1/2/ETS1 signaling 264. In a course of our study on 
DMF we noticed that DMF induces phosphorylation of ERK1/2, accompanied by 
phosphorylation of ETS1 (Figure 31). We therefore verified with Western blot and 
quantitative PCR the protein and gene expression of MMP-1, which is 
upregulated upon 24 h of DMF treatment, however TGFβ treatment did not 
significantly downregulated MMP1 levels in lung fibroblasts (Figure 31).  
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Figure 31 DMF induces MMP1 expression via ERK1/2 and ETS1 pathway. HC 
and SSc lung fibroblasts were treated for indicated periods of time with TGFβ 
and DMF. Representative western blots and densitometric quantification are 
shown. Relative gene expression was measured with qPCR. n=3 cell lines per 
group. *P<0.05, **P<0.01, ***P<0.001. 
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Discussion 
Despite significant progress in elucidating the mechanisms of fibrosis, a 
cure for fibrotic diseases, including SSc, is not yet available. The difficulties of 
finding such a cure stem in part from the complexity of the fibrotic process that 
involves not only activation of numerous signaling pathways in fibroblasts, but 
also dysregulation of immune cells. In attempt to find a potential treatment for 
SSc, we focused on DMF, because of its distinct anti-inflammatory and anti-
oxidative activities (see Chapter 5).  
The anti-fibrotic potential of DMF was validated in vivo in a bleomycin-
induced lung and skin fibrosis model in which DMF efficiently prevented 
pathological collagen deposition and changes in pulmonary and skin morphology, 
and significantly reduced expression of pro-inflammatory and pro-fibrotic genes.  
We show that in fibroblasts isolated from lungs and skin of SSc patients or 
healthy controls, DMF diminished both basal and TGFβ-induced pro-fibrotic gene 
expression. In contrast to a previous report 219, DMF did not affect canonical 
TGFβ signaling, as phosphorylation of SMAD2/3 and SMAD1/5 and protein 
levels of SMADs were not significantly altered by DMF. This discrepancy could 
be explained by the differences in cells used in the respective studies (rat kidney 
fibroblasts vs human lung fibroblasts). Importantly, TGFβ-induced expression of 
pro-fibrotic and pro-inflammatory genes was efficiently blocked by DMF even in 
the absence of NRF2, whereas upregulation of NOX4 was not dependent on 
NRF2. This suggests that DMF blocks TGFβ transcriptional response through 
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NOX4-independent pathways in vitro. However, reduction of NOX4 might 
contribute to the anti-fibrotic action of DMF in vivo, as NOX4 is linked to the 
development of pulmonary fibrosis 265,266.  
Our exploration of the effects of DMF on TGFβ-induced fibrotic process in 
human lung fibroblasts has revealed a novel mechanism of action for DMF. DMF 
promotes the degradation of β-catenin and TAZ in human lung fibroblasts.  β-
catenin and YAP/TAZ are transcriptional effectors of the interconnected Wnt and 
Hippo pathways that play essential roles in tissue homeostasis by regulating 
genes determining cell fate, proliferation and apoptosis 62,267. Both Wnt and 
Hippo pathways have been implicated in pulmonary fibrosis and PAH 
63,72,73,255,268, and are considered promising therapeutic targets for fibrotic 
disease. Indeed, blocking Wnt signaling, downregulating β-catenin or YAP/TAZ 
prevented fibroblast activation in vitro and fibrosis development in animal models 
68,73,269. Here we show that DMF promotes proteasomal, βTRCP-dependent 
degradation of β-catenin and TAZ, whereas TGFβ induces stabilization of those 
proteins, which may explain, at least in part, antagonistic effect of DMF on TGFβ 
signaling. Notably, in the βTRCP silencing experiments we observed different 
patterns of stabilization of β-catenin and TAZ by TGFβ, which might be due to 
the unknown effects of TGFβ and DMF on posttranslational regulators controlling 
stability of those proteins. Although our study focused on regulation of ECM 
production, it is worth noting that β-catenin and TAZ might contribute to other 
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features of fibrosis in SSc, including hyperproliferation and reduced apoptosis of 
fibroblasts, and these pathways may also be affected by DMF treatment 255,270.   
Additionally, we show that DMF mediates proteasome-mediated 
degradation of a transcriptional activator, Sp1. Given the central role of Sp1 in 
basal and TGFβ-induced expression of ECM genes its degradation may 
represent an important mechanism of the anti-fibrotic effects of DMF 271,272. 
Finally, DMF induces expression of important anti-fibrotic protein MMP1 through 
ERK1/2 /ETS1. As described before in an experimental liver fibrosis model 273, 
delivery of MMP-1 might help to resolve existing fibrosis. Although activation of 
ERK1/2 signaling is considered as pro-proliferative pathway, DMF, as previously 
described 274, inhibits fibroblast proliferation.  
Taken together, DMF can inhibit bleomycin-induced fibrosis in lungs and 
skin in vivo and pro-fibrotic TGFβ - induced signaling in fibroblasts in vitro. The 
mechanism of anti-fibrotic action is pleiotropic and involves newly identified 
proteasomal degradation of pro-fibrotic Sp1, TAZ and β-catenin and induction of 
anti-fibrotic MMP1.
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CHAPTER 7- SUMMARY AND CONCLUSIONS 
Healthy tissue homeostasis depends on the proper functioning of various 
physiological systems, including vasculature. Maintaining endothelial 
homeostasis is essential to keep the vasculature in a quiescent state. The 
consequence of vascular injury and dysfunction may be devastating, manifesting 
as occlusion and loss of small vessels, as well as tissue hypoxia and fibrosis. 
While misregulation of a variety of molecular pathways can contribute to 
endothelial dysfunction, the exact pathological mechanism remains unclear. One 
of the known perturbations in SSc- associated vasculopathy is an altered 
endothelial transcriptome. 
ERG and FLI1 are transcription factors that are abundant in healthy, 
quiescent endothelium and promote expression of cell-cell contact molecules and 
ensure endothelial barrier integrity. ERG maintains endothelium in a non-
activated state by repressing a range of pro-inflammatory genes. Upon vascular 
injury, endothelial levels of ERG and FLI1 significantly decrease, leading to a 
chain of pro-inflammatory events (Figure 32). This thesis presents a new 
mechanism by which ERG and FLI1 synergistically regulate vascular 
homeostasis in lungs. In iPAH and SSc patients, as well as chronically hypoxic 
mice, ERG levels are downregulated in pulmonary vasculature. Mechanistically, 
simultaneous downregulation of ERG and FLI1 results in synergistic upregulation 
of interferon pathway genes in vitro, and Erg/Fli1 double haploinsufficiency in 
mice leads to elevated lung inflammation. Both increased and chronic pro-
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inflammatory signaling and immune cell tissue infiltration in the lungs inevitably 
promotes vascular remodeling and fibrotic changes, which are hallmarks of SSc-
associated pulmonary complications. 
The question that remains unanswered is the exact mechanism of 
interferon genes activation in absence of ERG and FLI1. The main mechanism of 
interferon-stimulated gene activation is through binding of the interferon-
stimulated gene factor 3 (ISGF3) complex, which is composed of STAT1, STAT2 
and IFN-regulatory factor 9 (IRF9), to IFN-stimulated response element (ISRE) 
sequences 275. STAT proteins are constitutively present in the cell during 
homeostasis and their activity is regulated via phosphorylation. Therefore one 
possibility is that ERG/FLI1 depletion leads to STAT phosphorylation, which 
could be easily evaluated in vitro through the use of phospho-specific antibodies. 
Another possibility is that ERG/FLI1 competes with STAT for binding to the 
interferon gene promoter. Indeed, one of the known STAT1 binding sites in 
the IFNB1 promoter (-132 to -140) overlaps with the ERG binding site (-129 to -
138) presented in this work. In addition, we demonstrated that ERG/FLI1 
silencing upregulates IRF9 expression, a ISGF3 complex component, which 
might be an augmenting factor in interferon gene expression. Another possible 
mechanism could be the effect of ERG/FLI1 depletion on epigenetic chromatin 
modifications. It was previously demonstrated that under quiescent conditions 
FLI1 recruits HDAC1/p300 and suppresses gene expression by chromatin 
remodeling through histone deacetylation 276. Therefore it should be tested 
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whether ERG/FLI1 depletion leads to the altered acetylation profile of 
the IFNB1 gene promoter, thereby contributing to its transcriptional activation. 
Another important addition to revealing the in vivo role of ERG and FLI1’s 
synergistic regulation in endothelium would be generation of inducible Erg Fli1 
endothelial knockout mice. The double heterozygous mice tested in this thesis 
were not endothelial specific, therefore contribution of other cell types such as 
hematopoietic cells cannot be ruled out. In the future, mice should be derived by 
the inducable cre-lox system under the VE Cadherin promoter to ensure gene 
knockouts are specific to the endothelium.  
GATA6 is another transcription factor important for the maintenance of 
endothelial cell function. Decreased levels of vascular GATA6 have been shown 
in the lung tissue of PAH patients. This work demonstrates, for the first time, that 
GATA6 is an essential regulator of endothelial redox balance (Figure 32). 
Downregulation of endothelial GATA6 in vivo and in vitro results in augmented 
ROS levels and pronounced oxidative damage in lungs. GATA6 depletion 
corresponds with decreased anti-oxidative SOD and GPX enzymes expression 
and activity. Therefore, we identified a novel mechanism in which loss of GATA6 
leads to insufficient ROS clearance and redox imbalance. Importantly, oxidative 
stress is well known to promote endothelial dysfunction and vascular damage, 
and is implicated in the pathogenesis of SSc.  
An important question regarding GATA6 that remained to be answered is 
the mechanism of SOD and GPX regulation, which, to our knowledge, does not 
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involve direct binding of GATA6 to the promoter regions of these genes(data not 
shown). Another intriguing question is what type of signalling leads to the 
downregulation of GATA6 in ECs and if replenishing GATA6 levels in vitro and in 
vivo would protect from pro-oxidative and pro-inflammatory signaling in lung.  
Interestingly, many of the consequences of ERG, FLI1 and GATA6 
depletion are targetable by DMF, a known anti-inflammatory and anti-oxidative 
agent that we tested in vitro and in vivo PAH models (Figure 32).  
We also found that DMF can directly and indirectly inhibit fibroblast 
activation and ECM production, thereby stopping fibrogenic processes in tissue. 
Possibly the most direct anti- fibrotic effects of DMF on fibroblasts derive from 
increased proteasomal degradation of Sp1, the main regulator of the collagen 
type 1 gene, and an increased expression of MMP1, a metalloproteinase that 
degrades extracellular collagen fibers. In addition, this work demonstrates a new 
anti-fibrotic mechanism of action for DMF via enhanced degradation of TAZ/YAP 
and β-catenin. Previous studies showed that these mediators are constitutively 
activated in human fibrotic tissues in SSc and their inhibition prevents 
development of fibrosis in animal models 69,73. Whereas TAZ/YAP promotes 
expression of known pro-fibrotic mediators, β-catenin is not known to directly 
regulate ECM gene expression, and its pro-fibrotic effects are thought to depend 
on fibroproliferative and migratory activities as well as a cross-talk with TGFβ 
signaling. Further studies are needed to elucidate the role of Hippo and Wnt 
signalling pathways in fibrotic process. For example, investigating whether 
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fibroblast specific knockout mice are protected from fibrosis or PAH, followed by 
transcriptomic and proteomic analysis would help in understanding the role of 
these factors in pathogenesis of SSc. The literature on the interplay between 
TGFβ, Wnt and Hippo pathways suggest that the interaction with SMAD proteins 
is a common denominator for all three pathways 70. Therefore, It would be useful 
to test whether DMF alters the interactions with SMAD proteins. 
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Figure 32 Schematic illustrating integrated anti-inflammatory, anti-oxidative and 
anti-fibrotic actions of DMF. 
  
  
124 
Another important point is that the translational research in this thesis 
proves that DMF treatment is effective in ameliorating PAH in hypoxic mice, most 
likely through integration of various anti-inflammatory and anti-fibrotic 
mechanisms. The beneficial effect of DMF on ECs can translate in vivo not only 
by ameliorating endothelial damage and dysfunction, but also by inhibiting 
vascular muscularization. In our experiments DMF inhibits hypoxia-induced 
expression of pro-proliferative factors such as CTGF, ET-1 and PDGF by ECs in 
vitro.  
It is a widely accepted notion that the paracrine crosstalk between ECs and 
SMCs is largely responsible for promoting SMCs proliferation and migration 277. 
Another effect that could contribute to the inhibition of PAH development in 
hypoxic mice, that we did not address directly, is effect of DMF on heart. Chronic 
hypoxia induces an increase in a RV weight indicating RV hypertrophy, which is 
mediated by pressure overload caused by changes in pulmonary vasculature 
278,279. We showed that DMF ameliorates the vascular muscularization in the 
lung, which could partially explain almost complete inhibition in RV weight 
increase; it would be however necessary to perform experiments on isolated 
heart hypertrophy model to verify if DMF has direct cardio-protective properties. 
This work has a solid foundation for further pharmacological investigation in 
physiologically-relevant mouse PAH models and also in larger animal models. 
Used in our studies, the chronic hypoxia mouse model present some limitations 
as to fully represent the human-like disease. First, the hypoxia-induced PAH is 
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reversible in mice upon return to normoxia. These mice also lack the complex 
vascular lesions and marked increase in inflammation seen in PAH patients. One 
possibility to overcome these problems would be to use different models, 
including genetic mouse models of PAH, such as BMR2 knockout or IL-6 
overexpression in combination with hypoxia, or chemical inhibition of VEGF with 
SU5416 in combination with hypoxia. These mice have been shown to have 
higher RVSP and more severe vascular remodeling when compared to hypoxia 
alone 280. However, the most acceptable rodent model of PAH is a monocrotaline 
injury rat model and it should be included in future DMF studies.  Ultimately, 
given that DMF is an FDA-approved drug with a favorable safety profile, it should 
be tested in clinical trials involving SSc-PAH patients. 
Current therapies for PAH are focused on promoting vasodilation and, with 
an exception of ET-1 receptor blocker, have little effect on that fixed mechanical 
vascular obstruction, which is the predominant cause of increased PAP in most 
SSc-PAH patients. Here we show that DMF, in addition to inhibiting ET-1 
expression in ECs, SMCs fibroblasts, as well as in the whole lung tissue of 
chronically hypoxic mice, blocks multiple pathological pathways contributing to 
vascular remodeling in PAH, including inflammation, fibrosis and oxidative stress. 
A promising therapy for PAH is NRF2-based therapy with bardoxolone methyl 
(CDDO-Me), a NRF2 inducer, which has shown encouraging results in Phase II 
clinical trials in PAH patients (http://reatapharma.com/reata-announces-initial-
  
126 
phase-2-pulmonary-arterial-hypertension-data-for-bardoxolone-methyl-and-
planned-initiation-of-phase-3-study/).  
The most important unanswered question regarding DMF is whether the 
different molecular pathways that are affected by DMF could be regulated by 
one, integrated upstream mechanism. To answer this question the receptor for 
DMF on ECs and fibroblasts needs to be characterized. Given that DMF is an 
agonist of HCAR2 in immune cells, which is a G protein coupled receptor 
(GPCR), it is highly possible that other GPCRs are involved in DMF signaling in 
non-immune cells. In addition, it has been shown that DMF can modify certain 
proteins intra-cellulary via direct interaction, including p65 229  and KEAP1 281, 
which suggest that DMF effects might be very complex and an upstream 
signaling mechanism may not exist. It is worth mentioning that there is also the 
possibility that DMF can enter the TCA cycle and possibly modulate cellular 
metabolism. As a proof of this concept it was recently demonstrated by a 
metabolomics studies that DMF treatment in vitro alters levels of citric acid cycle 
intermediates, glutathione and lipids 282. Finally, the in vivo action of DMF 
includes modulation of immune cell number and activity 283, which is an additional 
obscuring factor when trying to find a universal mechanism of its action. 
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